

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C12N 15/12, C07K 14/705, A01K 67/027, C12N 5/10, C12Q 1/68, G01N 33/50		A1	(11) International Publication Number: <b>WO 00/60069</b>
		(43) International Publication Date: 12 October 2000 (12.10.00)	
(21) International Application Number: PCT/CA00/00354		(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BI, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 3 April 2000 (03.04.00)			
(30) Priority Data: 60/127,452 1 April 1999 (01.04.99) US 60/173,826 30 December 1999 (30.12.99) US			
(71) Applicant: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA/CA); 106, Simeco Hall, 27 King's College Circle, Toronto, Ontario M5S 1A1 (CA).		<p>Published</p> <p>With international search report.</p> <p>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>	
(72) Inventors: ST. GEORGE-HYSLOP, Peter, H.; 210 Richview Avenue, Toronto, Ontario M5P 3G3 (CA). FRASER, Paul, E.; 611 Windermere Avenue, Toronto, Ontario M6S 3L9 (CA).			
(74) Agent: RAE, Patricia, A.; Sim & McBurney, 6th floor, 330 University Avenue, Toronto, Ontario M5G 1R7 (CA).			
(54) Title: A PRESENILIN ASSOCIATED MEMBRANE PROTEIN AND USES THEREOF			
(57) Abstract			
<p>Presenilin Associated Membrane Protein (PAMP), and nucleic acids encoding this protein, are provided. PAMP and PAMP nucleic acids provide diagnostic and therapeutic tools for evaluating and treating or preventing neurodegenerative diseases. In a specific embodiment, mutations in PAMP are diagnostic for Alzheimer's Disease or spina bifida. The invention further relates to screening, particularly using high-throughput screens and transgenic animal models, for compounds that modulate the activity of PAMP and presenilins. Such compounds, or gene therapy with PAMP, can be used in treating neurodegenerative diseases, particularly Alzheimer's Disease. In addition, the invention provides PAMP mutants, nucleic acids encoding for PAMP mutants, and transgenic animals expressing PAMP mutants, which in a preferred aspect result in biochemical changes similar to those induced by mutations in <math>\beta</math>APP, PS1, or PS2 associated with familial Alzheimer's Disease.</p>			
<p>Hum: 1 NATAGGGGADPGSRGLLRLLSFCVLLAGLCGRGNSVERKIYIPLNKATPCVRLNATHQI 60 Mou: NAT GGGG DPGSRGLL LLSF +LAGLC GNSVERKIYIPLNKATPCVRLNATHQI Dros: 1 A + +C A C R LK THQ C.eleg L + + +AG +C G S + + + C R N TH +</p> <p>Hum: 61 GCQSSISGDTGVIHVVEKEEDLQWLTGDPHPYVNLSEKHPTRDLMEKLGRTSRIAG 120 Mou: GCQSSISGDTGVIHVVEKEEDLQWLTGDPHPYVNLSEKHPTRDLMEKLGRTSRIAG Dros: GC S SG GV +H + + E DL + +L + P +PPY + + PTR + +L + + C.eleg GCQ + + + G +I + +K +ED + W + Y LL RD + +L + + +G</p> <p>Hum: 121 LAVSLTKEPSPASGPFBSVQCNDGFGVYNSGYEPFAHCRQWNSLNGCLAYEDFPFPI 180 Mou: LAV + L KP + S FSPSVQCNDGFG VNSGYEPFAH + + NN LG GLAYED FPFPI Dros: + + + + + FS + CPN G S S + + + NN G GL +EDF FPI C.eleg + +S + + + S +CPN Y E + E + NS G +GL D + +</p> <p>Hum: 161 FLEDEMETVKIKQCYQHNLQNSGASPTFLCANQLPFSHMAVISTATCKHRSISQSTF 240 Mou: FLEDEMETVKIKQCYQHNLQNSGASPTFLCANQLPFSHMAVISTATCKHRSISQSTF Dros: + + D + + + +CGD N + LCA + + + S N A + +T CHRS + + C.eleg + + + + +I + +CY N + + +P C N A + + C RR + F</p> <p>Hum: 241 SINPEIVCDPLSDYVNMWMLKPIINTGTLKPDORVVAATRLDSRF + VNVARGAESAV 299 Mou: SINPEIVCDPLSDYVNMWMLKPIINT + L +PD RVVVAATRLDSRF + VNVARGAESAV Dros: + + CDPL NV P + T T + + + + + RLO + + F V GA + + C.eleg + N + +C + H + + PI T + T + + + + RDS + + G S +</p> <p>Hum: 300 ASFTQLAAAEALQKAPDVTTLRNHGVFFPQGTDFYIGSSRMVYMEKGFPPVQNV 359 Mou: ASFTQLAAAEALQKAPDVTTLRNHGVFFPQGTDFYIGSSRMVYMEKGFPPVQNV Dros: F A LQ P + + NV +FV F GE + +DYIGS R VYMEK +P + +N + C.eleg S + + LAAA + +/QKA + + RN +F FF GE + +DYIGS Y ME KGF + + +</p>			

# FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## A PRESENILIN ASSOCIATED MEMBRANE PROTEIN AND USES THEREOF

FIELD OF THE INVENTION

- 5 The present invention relates generally to the field of neurological and physiological dysfunctions associated with neuropsychiatric and developmental diseases, especially Alzheimer's Disease. More particularly, the invention is concerned with the identification of proteins associated with neuropsychiatric and developmental diseases, especially
- 10 Alzheimer's Disease, and relates to methods of diagnosing these diseases, and to methods of screening for candidate compounds which modulate the interaction of a certain protein, specifically Presenilin Associated Membrane Protein ("PAMP"), with presenilin proteins.

BACKGROUND OF THE INVENTION

- 15 Alzheimer's Disease (AD) is a degenerative disorder of the human central nervous system characterized by progressive memory impairment and cognitive and intellectual decline during mid to late adult life (Katzman, *N Eng J Med* 1986;314:964-973). The disease is accompanied by
- 20 a constellation of neuropathologic features principal amongst which are the presence of extracellular amyloid or senile plaques, and neurofibrillary tangles in neurons. The etiology of this disease is complex, although in some families it appears to be inherited as an autosomal dominant trait. Genetic studies have identified three genes associated with the development of AD, namely:
- 25 (1)  $\beta$ -amyloid precursor protein ( $\beta$ APP) (Chartier-Harlin *et al.*, *Nature* 1991;353:844-846; Goate *et al.*, *Nature* 1991;349:704-706; Murrell *et al.*, *Science* 1991;254:97-99; Karlinsky *et al.*, *Neurology* 1992;42:1445-1453; Mullan *et al.*, *Nature Genetics* 1992;1:345-347); (2) presenilin-1 (PS1) (Sherrington *et al.*, *Nature* 1995;375:754-760); and (3) presenilin-2 (PS2)
- 30 (Rogaev *et al.*, *Nature* 1995;376:775-778; Levy-Leahad *et al.*, *Science* 1995; 269:970-973).

- Abnormal processing of  $\beta$ APP with overproduction of amyloid- $\beta$  is also a feature of other CNS diseases, including inherited and sporadic forms of amyloid angiopathy, which presents with intracerebral bleeding (Levy
- 35 *et al.*, *Science* 1990;248:1124-1126). Thus, abnormalities of presenilin proteins and PS-interacting proteins may affect these diseases as well.

The presenilin genes (PS1 - *PS1* and PS2 - *PS2*) encode homologous polytopic transmembrane proteins that are expressed at low levels in intracellular membranes including the nuclear envelope, the endoplasmic reticulum, the Golgi apparatus and some as yet uncharacterized intracytoplasmic vesicles in many different cell types including neuronal and non-neuronal cells (Sherrington *et al.*, *supra*; Rogaev *et al.*, *supra*; Levy-Lahad *et al.*, *supra*; Doan *et al.*, *Neuron* 1996;17:1023-1030; Walter *et al.*, *Molec. Medicine* 1996;2:673-691; De Strooper *et al.*, *J. Biol. Chem.* 1997;272:3590-3598; Lehmann *et al.*, *J. Biol. Chem.* 1997;272:12047-12051; Li *et al.*, *Cell* 1997;90:917-927). Structural studies predict that the presenilins contain between six and eight transmembrane (TM) domains organized such that the N-terminus, the C-terminus, and a large hydrophilic loop following the sixth TM domain are located in the cytoplasm or nucleoplasm, while the hydrophilic loop between TM1 and TM2 is located within the lumen of membranous intracellular organelles (Doan *et al.*, 1996; De Strooper *et al.*, 1997; Lehmann *et al.*, 1997).

Missense mutations in the PS1 and PS2 genes are associated with the inherited forms of early-onset AD (Sherrington *et al.*, *Nature* 1995;375:754-760; Rogaev, *et al.*, *Nature* 1995;376:775-778; Levy-Lahad *et al.*, *Science* 1995;269:970-973). Several lines of evidence have also suggested roles in developmental, apoptotic signalling and in the regulation of proteolytic cleavage of the  $\beta$ -amyloid precursor protein ( $\beta$ APP) (Levitan *et al.*, *Nature* 1995;377:351-354; Wong *et al.*, *Nature* 1997;387:288-292; Shen *et al.*, *Cell* 1997;89:629-639; Wolozin *et al.*, *Science* 1996;274:1710-1713; De Strooper *et al.*, *Nature* 1998;391:387-390). Nevertheless, it remains unclear just how these putative functions are mediated, or how they relate to the abnormal metabolism of the  $\beta$ APP associated with PS1 and PS2 mutations (Martin *et al.*, *NeuroReport* 1995;7:217-220; Scheuner *et al.*, *Nature Med.* 1996;2:864-870; Citron *et al.*, *Nature Med.* 1997;3:67-72; Duff *et al.*, *Nature* 1996;383:710-713; Borchelt *et al.*, *Neuron* 1996;17:1005-1013).

PS1 and PS2 interact specifically with at least two members of the armadillo family of proteins; neuronal plakophilin-related armadillo protein (Paffenholtz *et al.*, *Differentiation* 1997; 61: 293-304; Paffenholtz *et al.*, *Exp Cell Res* 1999; 250: 452-464; Zhou *et al.*, *Neuroreport* 1997; 8: 2085-2090) and  $\beta$ -catenin, that are expressed in both embryonic and post-natal tissues. Moreover, the domains of PS1 and PS2 that interact with these proteins have

been identified. Mutations in PS1 and PS2 affect the translocation of  $\beta$ -catenin into the nucleus of both native cells and cells transfected with a mutant PS gene. These interactions and effects are described in detail in co-pending commonly assigned U.S. Application Serial No. 09/227,725, filed January 8, 1999, the disclosure of which is incorporated herein by reference.

The identification and cloning of normal as well as mutant PS1 and PS2 genes and gene products are described in detail in co-pending commonly assigned US Application Serial Nos. 08/431,048, filed April 28, 1995; 08/496,841, filed June 28, 1995; 08/509,359, filed July 31, 1995; and 08/592,541, filed January 26, 1996, the disclosures of which are incorporated herein by reference.

There is speculation that onset of AD may be associated with aberrant interactions between mutant presenilin proteins and normal forms of PS-interacting proteins, and these changes may increase or decrease interactions present with normal PS1, or cause interaction with a mutation-specific PS-interacting protein. Such aberrant interactions also may result from normal presenilins binding to mutant forms of the PS-interacting proteins. Therefore, mutations in the PS-interacting proteins may also be implicated in the development of AD.

While the identification of normal and mutant forms of PS proteins has greatly facilitated development of diagnostics and therapeutics, a need exists for new methods and reagents to more accurately and effectively diagnose and treat AD. In addition, further insights into PS proteins and their interaction with other components may lead to new diagnostic and treatment methods for other related CNS diseases.

#### SUMMARY OF THE INVENTION

Applicants have discovered that PS1 and PS2 interact specifically with a transmembrane protein, herein referred to as "Presenilin Associated Membrane Protein" or "PAMP", which is expressed in multiple tissues (e.g., brain, kidney, lung, etc.). The product of this gene is therefore implicated in the biochemical pathways affected in Alzheimer's Disease, and may also have a role in other dementias, amyloid angiopathies, and developmental disorders such as spina bifida. This gene, therefore, presents a new therapeutic target for the treatment of Alzheimer's Disease and other neurologic diseases. In addition, PAMP nucleic acids, proteins and peptides,

antibodies to PAMP, cells transformed with PAMP nucleic acids, and transgenic animals altered with PAMP nucleic acids that possess various utilities, as described herein for the diagnosis, therapy and continued investigation of Alzheimer's Disease and other neurodegenerative disorders.

- 5 Furthermore, mutant PAMP nucleic acids, proteins, or peptides, cells transfected with vectors comprising mutant PAMP nucleic acids, transgenic animals expressing mutant PAMP or peptides thereof, and their use in studying Alzheimer's Disease and other neurodegenerative disorders, or developing improved diagnostic or therapeutic methods for such disorders, are presented herein.

Thus, the invention provides isolated and purified presenilin associated membrane protein (PAMP), or a functional fragment thereof, as well as nucleic acids encoding a PAMP. Preferred nucleotide and amino acid sequences are provided herein. The invention further provides probes and primers for PAMP genes. Preferred embodiments include sequences of at least 10, 15 or 20 consecutive nucleotides selected from the disclosed sequences.

The invention also provides isolated and purified mutant PAMP, or a functional fragment thereof, as well as nucleic acids encoding a mutant PAMP, and probes and primers for PAMP genes. Preferred nucleotide and amino acid sequences are provided herein.

Using the nucleic acid and amino acid sequences disclosed herein, methods for identifying allelic variants or heterospecific homologues of a human PAMP and gene are provided. The methods may be practiced using nucleic acid hybridization or amplification techniques, immunochemical techniques, or any other technique known in the art. The allelic variants may include other normal human alleles as well as mutant alleles of PAMP genes which may be causative of Alzheimer's Disease or other CNS diseases. The heterospecific homologues may be from other mammalian species, such as mice, rats, dogs, cats or non-human primates, or may be from invertebrate species, such as *Drosophila melanogaster* or *Caenorhabditis elegans*. Thus, it is another object of the invention to provide nucleic acids that encode allelic or heterospecific variants of the disclosed sequences, as well as the allelic or heterospecific proteins encoded by them.

The invention also provides vectors, and particularly expression vectors (e.g., cos-Tet vector), which include any of the above-described

- nucleic acids. It is a further object of the invention to provide vectors in which normal or mutant PAMP nucleic acid sequences are operably joined to exogenous regulatory regions to produce altered patterns of expression, or to exogenous coding regions to produce fusion proteins. Conversely, it is
- 5 another object to provide nucleic acids in which PAMP regulatory regions are operably joined to exogenous coding regions, including standard marker genes, to produce constructs in which the regulation of PAMP genes may be studied and used in assays or therapeutics.

- The invention further provides host cells and transgenic animals
- 10 transformed with any of the above-described nucleic acids of the invention. The host cells may be prokaryotic or eukaryotic cells and, in particular, may be gametes, zygotes, fetal cells, or stem cells useful in producing transgenic animal models. In one embodiment, the transgenic animal contains a transgene encoding a normal or mutant PAMP, which is expressed in neural
- 15 cells such that expression can be detected, e.g., by detecting PAMP, mRNA, or protein, and more preferably by detecting a neuroprotective or a neurodegenerative phenotype. For example, the animal might manifest one or more symptoms of a neurodegenerative disease. The animal may be a vertebrate or an invertebrate. In a preferred embodiment, the transgenic
- 20 animal is a mouse, and the transgene encodes a human PAMP. The transgenic animal may further comprise a second transgene encoding a normal or mutant PS1, PS2, or  $\beta$ APP.

- In another embodiment, the invention provides an animal containing a nucleic acid that expresses a PAMP or a mutant PAMP at a
- 25 higher or lower level relative to the expression level in a wild-type animal. The animal may be prepared by homologous recombination-mediated targeting of endogenous PAMP nucleic acid. In a preferred embodiment, the animal is prepared by translocation of P-elements or chemical mutagenesis.

- The invention also provides a reconstituted system for
- 30 measuring PAMP activity, comprising PAMP, a mutant PAMP, or functional fragments thereof, and a PAMP substrate. The reconstituted system may be a whole cell. Preferably, the whole cell contains a first nucleic acid that expresses said PAMP and a second nucleic acid that expresses the substrate. Preferably, the substrate comprises PS1 protein, PS2 protein,
- 35  $\beta$ APP, or a surrogate synthetic substrate protein such as Notch, which undergoes proteolytic processing events similar to those of  $\beta$ APP (Haass C

and Selkoe DJ. Nature 1998; 391: 387-390; De Strooper B, *et al.*, Nature 1999; 398:518-522; Song W, *et al.*, Proc Natl Acad Sci USA 1999; 96: 6959-6963.; Struhl G and Greenwald I, Nature 1999; 398: 522-525; Ye Y, *et al.*, Nature 1999; 398: 525-529.).

5           The invention provides, in addition, a complex between a PAMP, or a mutant PAMP, and an agent which provides a detectable conformational or functional change in the PAMP upon interaction with a substance being analyzed for activity against a neurodegenerative disease. The complex may further comprise PS1 protein, PS2 protein or  $\beta$ APP.

10           The invention also provides a method for detecting a mutation in PAMP associated with Alzheimer's or a related neurological disorder, comprising obtaining a nucleic acid sample from an individual diagnosed with or suspected of having a neurodegenerative disorder, and sequencing a gene encoding PAMP from said sample.

15           The invention also provides a method for diagnosing individuals predisposed to or having a neurodegenerative disorder, comprising obtaining a nucleic acid sample from an individual diagnosed with or suspected of having a neurodegenerative disorder, and sequencing a gene encoding PAMP from said sample.

20           The invention also provides a method for diagnosing individuals predisposed to or having a neurodegenerative disorder, comprising obtaining cells that contain nucleic acid encoding PAMP, and under non-pathological conditions, transcribe the nucleic acid, and measuring a level of transcriptional activity of the nucleic acid.

25           The invention further provides a method for diagnosing individuals predisposed to or having a neurodegenerative disorder, comprising obtaining cells from an individual that express nucleic acid encoding PAMP, or isolating PAMP from said individual, and measuring PAMP activity, for example PAMP expression levels. In an alternative  
30           embodiment, the activity or abundance of a PAMP substrate may be measured.

          The invention also provides a method for identifying putative agents having anti-neurodegenerative activity, comprising administering one or more putative agents to a transgenic animal and detecting a change in  
35           PAMP activity.



The invention also provides a method for identifying putative agents having anti-neurodegenerative activity, comprising adding one or more said agents to the reconstituted system described above, and detecting a change in PAMP activity.

- 5       The invention also provides a method for identifying putative agents having anti-neurodegenerative activity, comprising adding one or more said agents to the complex described above, and detecting a conformational change in PAMP.

- 10       The invention also provides a method for identifying proteins that interact with PAMP, comprising contacting said substance with the reconstituted system discussed above, and detecting a change in PAMP activity.

- 15       Further the invention provides for a method for identifying substances that modulate PAMP activity, comprising contacting a sample containing one or more substances with PAMP, or a PAMP mutant, or functional fragments thereof, and a PAMP substrate, measuring PAMP activity, and determining whether a change in PAMP activity occurs. In a preferred embodiment, the substance is a PAMP inhibitor. In another preferred embodiment, the substance stimulates PAMP activity.

- 20       These and other aspects of the invention are further elaborated in the Detailed Description of the Invention and Examples, *infra*.

#### DESCRIPTION OF THE DRAWINGS

- 25       FIGURE 1A and 1B. Predicted amino acid sequences for human (SEQ ID NO:14), mouse (SEQ ID NO:16), *D.melanogaster* (SEQ ID NO:18) and *C.elegans* (SEQ ID NO:12) orthologues. Residues not conserved in non-human PAMP are blank, conserved residues are aligned, similar residues are denoted by "+".

#### DETAILED DESCRIPTION OF THE INVENTION

- 30       While PS1 and PS2 have been implicated in proper processing of  $\beta$ APP, and mutations in these proteins have been associated with Alzheimer's Disease, further understanding of the development and progression of this disease, as well as other neurodegenerative diseases, requires a more complete understanding of the functions of the prehelins
- 35

and other proteins with which they interact. The present invention advantageously identifies such a protein.

### PAMP

5 The invention is based, in part, on the discovery of a novel Type I transmembrane protein that interacts with PS1 and PS2, and with the  $\alpha$ - and  $\beta$ -secretase derived fragments of  $\beta$ APP. The protein has been termed "Presenilin Associated Membrane Protein" (PAMP). As referred to herein, "PAMP" means a native or mutant full-length protein, or fragments thereof, 10 that interacts with the PAMP-interacting domain of a presenilin protein. PAMP is also known under the name "Nicastrin". Human, murine, *D. melanogaster* and *C. elegans* orthologues are provided.

Experimental data indicate that PAMP, PS1, and PS2 exist in the same high molecular weight protein complex, and PAMP and PS1 are 15 both co-localized to intracellular membranes in the endoplasmic reticulum and Golgi apparatus. Abolition of functional expression of a *C. elegans* homologue of this protein leads to the development of *Notch*-like developmental defects. This shows that PAMP is also intimately involved in the processing of not only  $\beta$ APP, but also other molecules, such as *Notch* and its homologues. From 20 expressed sequence tags (EST) databases, it is apparent that, like PS1 and PS2, PAMP is expressed in multiple tissues.

Various structural features characterize PAMP (GenBank; Accession No. Q92542; SEQ ID NO: 14). The nucleotide sequence (SEQ ID NO: 13) of human PAMP predicts that the gene encodes a Type 1 25 transmembrane protein of 709 amino acids (SEQ ID NO: 14), the protein having a short hydrophilic C-terminus (~20 residues), a hydrophobic transmembrane domain (15-20 residues), and a longer N-terminal hydrophilic domain which contains several potentially functional sequence motifs as listed below in Table 1. The PAMP sequence also contains a Trp-Asp (WD) repeat 30 (residue 226), at least one "DTG" motif (residues 91 - 93) present in eukaryotic aspartyl proteases, as well as several "DTA/DTAE" motifs (residues 480 - 482, 504 - 506) present in viral aspartyl proteases. There are also four conserved cysteine residues in the N-terminal hydrophilic domain (Cys<sub>195</sub>, Cys<sub>213</sub>, Cys<sub>230</sub>, and Cys<sub>248</sub> in human PAMP) having a periodicity of 35 16-17 residues, which may form a functional domain (e.g., a metal binding domain or disulfide bridge for tertiary structure stabilization). Subdomains of

PAMP have weak homologies to a variety of peptidases. For example, residues 322 - 343, 361 - 405, and 451 - 466 have 46% ( $p = 0.03$ ) similarity to another hypothetical protein, *C. elegans* aminopeptidase hydrolase precursor signal antigen transmembrane receptor zinc glycoprotein (SWISS-PROT; 5 www.expasy.ch/sprot; Accession No. Q93332).

Table 1 - Potential functional sequence motifs in PAMP (SEQ ID NO: 14).

Potential function:	PAMP Residue
N-asparaginyl glycosylation	44, 101, 290, 492, 698, 964, 1353, 1772, 2209, 2675, 3183, 3715, 4279, 4854, 5436, and 6050.
Glycosaminoglycan attachment	403
Myristolation	4, 37, 102, 226, 376, 548, 757, 1055, 1497, 1947, 2455, and 3035.
Phosphorylation sites for cAMP- and cGMP-dependent protein kinase	231
Phosphorylation sites for protein kinase C	114, 383, 724, 1109, 1499, 1983, 2598, and 3223
Phosphorylation sites for casein kinase II	7, 289, 652, 1026, 1483, 1951, 2425, 3068, and 3717

- The invention is further based on the identification of conserved
- 5 functional domains, based on comparison and evaluation of the predicted amino acid sequences of human (SEQ ID NO: 14), murine (SEQ ID NO: 16), *D. melanogaster* (SEQ ID NO: 18), and *C. elegans* (SEQ ID NO: 12) orthologues of PAMP. "PAMP" can be characterized by the presence of conserved structural features, relative to orthologues from *D. melanogaster*
- 10 and *C. elegans*. Nucleotide sequences encoding homologous hypothetical proteins exist in mice multiple EST, and *C. elegans* (GenBank; [www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov); Accession No. Z75714; 37% similarity,  $p = 8.7e^{-26}$ ) (Wilson *et al.*, *Nature* 1994; 368: 32-38). These hypothetical murine and nematode proteins have a similar topology and contain similar functional
- 15 motifs to human PAMP. The existence of such homology predicts that similar proteins will be detected in other species including *Xenopus*, and Zebra fish, to mention a few such possibilities. By comparing the predicted amino acid sequences of human (SEQ ID NO: 14), murine (SEQ ID NO: 16), *D. melanogaster* (SEQ ID NO: 18), and *C. elegans* (SEQ ID NO: 12) PAMP
- 20 proteins, we have deduced a series of conserved functional domains. One domain has chemical similarities to cyclic nucleotide binding domains of other proteins, and may have some regulatory role on a potential complex formed between PS1:PAMP and the C-terminal fragment of  $\beta$ APP, derived either from  $\alpha$ - or  $\beta$ -secretase. These putative functional domains are sites for therapeutic

target development by deploying drugs which might interact with these sites to modulate  $\beta$ APP processing via this complex.

The term "PAMP" also refers to functionally active fragments of the protein. Such fragments include, but are not limited to, peptides that contain an epitope, e.g., as determined by conventional algorithms such as hydrophilicity/hydrophobicity analysis for antibody epitopes, and amphipathicity or consensus algorithms for T cell epitopes (Spouge, *et al.*, J. Immunol., 138:2204, 1987; Margalit, *et al.*, J. Immunol., 138:2213, 1987; Rothbard, Ann. Inst. Pateur., 137E:518, 1986; Rothbard and Taylor, EMBO J., 7:93, 1988). More preferably, a functionally active fragment of PAMP is a conserved domain, relative to the *D. melanogaster* and *C. elegans* orthologues. A specific functionally active fragment of PAMP is a fragment that interacts with PS1 or PS2, or both.

PAMP also encompasses naturally occurring variants, including other mammalian PAMPs (readily identified, as shown herein for murine PAMP, based on the presence of the structural features set forth above), allelic variants of PAMP from other human sources (including variants containing polymorphisms that are predictive of disease propensity or of response to pharmacological agents), and mutant forms of PAMP or PAMP genes that are associated with neurological diseases and disorders (such as spina bifida), particularly neurodegenerative diseases (such as AD). Also included are artificial PAMP mutants created by standard techniques such as site directed mutagenesis or chemical synthesis.

A PAMP "substrate" may be a polypeptide or protein, or any other type of compound, with which PAMP interacts physiologically. Examples of PAMP substrates include PS1, PS2, and  $\beta$ APP. Furthermore, a PAMP "ligand" may be a polypeptide, protein, lipid, carbohydrate, vitamin, mineral, amino acid, or any other type of compound which binds to PAMP. Hypothetically, PAMP may function as a receptor which modulates PS1/PS2/ $\beta$ APP processing in response to signal (ligand) dependent interactions with PAMP.

#### Definitions

In accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully

- in the literature. See, e.g., Sambrook, Fritsch & Maniatis, *Molecular Cloning: A Laboratory Manual*, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (herein "Sambrook et al., 1989"); *DNA Cloning: A Practical Approach*, Volumes I and II (D.N. Glover ed. 1985); *Oligonucleotide Synthesis* (M.J. Gait ed. 1984); *Nucleic Acid Hybridization* (B.D. Hames & S.J. Higgins eds. (1985)); *Transcription And Translation* (B.D. Hames & S.J. Higgins, eds. (1984)); *Animal Cell Culture* (R.I. Freshney, ed. (1986)); *Immobilized Cells And Enzymes* (IRL Press, (1986)); B. Perbal, *A Practical Guide To Molecular Cloning* (1984); F.M. Ausubel et al. (eds.), *Current Protocols in Molecular Biology*, John Wiley & Sons, Inc. (1994).

If appearing herein, the following terms shall have the definitions set out below

- The use of italics (e.g., *PAMP*) indicates a nucleic acid molecule (cDNA, mRNA, gene, etc.); normal text (e.g., PAMP) indicates the polypeptide or protein.

In a specific embodiment, the term "about" or "approximately" means within 20%, preferably within 10%, and more preferably within 5% of a given value or range. Alternatively, particularly in biological systems which are often responsive to order of magnitude changes, the term about means 20 within an order of magnitude of a given value, preferably within a multiple of about 5-fold, and more preferably within a factor of about 2-fold of a given value.

As used herein, the term "isolated" means that the referenced material is free of components found in the natural environment in which the material is normally found. In particular, isolated biological material is free of cellular components. In the case of nucleic acid molecules, an isolated nucleic acid includes a PCR product, an isolated mRNA, a cDNA, or a restriction fragment. In another embodiment, an isolated nucleic acid is preferably excised from the chromosome in which it may be found, and more preferably is no longer joined to non-regulatory, non-coding regions, or to other genes, located upstream or downstream of the gene contained by the isolated nucleic acid molecule when found in the chromosome. In yet another embodiment, the isolated nucleic acid lacks one or more introns. Isolated nucleic acid molecules can be inserted into plasmids, cosmids, artificial chromosomes, and the like. Thus, in a specific embodiment, a recombinant nucleic acid is an isolated nucleic acid. An isolated protein may be associated

with other proteins or nucleic acids, or both, with which it associates in the cell, or with cellular membranes if it is a membrane-associated protein. An isolated organelle, cell, or tissue is removed from the anatomical site in which it is found in an organism. An isolated material may be, but need not be, purified.

The term "purified" as used herein refers to material that has been isolated under conditions that reduce or eliminate unrelated materials, i.e., contaminants. For example, a purified protein is preferably substantially free of other proteins or nucleic acids with which it is associated in a cell; a purified nucleic acid molecule is preferably substantially free of proteins or other unrelated nucleic acid molecules with which it can be found within a cell.

As used herein, the term "substantially free" is used operationally, in the context of analytical testing of the material. Preferably, purified material substantially free of contaminants is at least 50% pure; more preferably, at least 90% pure, and more preferably still at least 99% pure. Purity can be evaluated by chromatography, gel electrophoresis, immunoassay, composition analysis, biological assay, and other methods known in the art.

The term "host cell" means any cell of any organism that is selected, modified, transformed, grown, or used or manipulated in any way, for the production of a substance by the cell, for example the expression by the cell of a gene, a DNA or RNA sequence, a protein or an enzyme. Host cells can further be used for screening or functional assays, as described *infra*. A host cell has been "transfected" by exogenous or heterologous DNA when such DNA has been introduced inside the cell. A cell has been "transformed" by exogenous or heterologous DNA when the transfected DNA is expressed and effects a function or phenotype on the cell in which it is expressed. The term "expression system" means a host cell transformed by a compatible expression vector and cultured under suitable conditions e.g. for the expression of a protein coded for by foreign DNA carried by the vector and introduced to the host cell.

Proteins and polypeptides can be made in the host cell by expression of recombinant DNA. As used herein, the term "polypeptide" refers to an amino acid-based polymer, which can be encoded by a nucleic acid or prepared synthetically. Polypeptides can be proteins, protein fragments, chimeric proteins, etc. Generally, the term "protein" refers to a

polypeptide expressed endogenously in a cell, e.g., the naturally occurring form (or forms) of the amino acid-based polymer.

5 A "coding sequence" or a sequence "encoding" an expression product, such as a RNA, polypeptide, protein, or enzyme, is a nucleotide sequence that, when expressed, results in the production of that RNA, polypeptide, protein, or enzyme, i.e., the nucleotide sequence encodes an amino acid sequence for that polypeptide, protein or enzyme. A coding sequence for a protein may include a start codon (usually ATG) and a stop codon.

10 The coding sequences herein may be flanked by natural regulatory (expression control) sequences, or may be associated with heterologous sequences, including promoters, internal ribosome entry sites (IRES) and other ribosome binding site sequences, enhancers, response elements, suppressors, signal sequences, polyadenylation sequences, introns, 5'- and 3'- non-coding regions, and the like. The nucleic acids may also be modified by many means known in the art. Non-limiting examples of such modifications include methylation, "caps", substitution of one or more of the naturally occurring nucleotides with an analog, and internucleotide modifications.

20 The term "gene", also called a "structural gene" means a DNA sequence that codes for or corresponds to a particular sequence of ribonucleic acids or amino acids which comprise all or part of one or more proteins, and may or may not include regulatory DNA sequences, such as promoter sequences, which determine for example the conditions under which the gene is expressed.

25 A "promoter sequence" is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence. For purposes of defining the present invention, the promoter sequence is bounded at its 3' terminus by the transcription initiation site and extends upstream (5' direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background.

30 A coding sequence is "under the control" or "operatively associated with" of transcriptional and translational control sequences in a cell when RNA polymerase transcribes the coding sequence into mRNA, which



then may be trans-RNA spliced (if it contains introns) and translated into the protein encoded by the coding sequence.

The terms "express" and "expression" mean allowing or causing the information in a gene or DNA sequence to become manifest, for example  
5 producing a protein by activating the cellular functions involved in transcription and translation of a corresponding gene or DNA sequence. A DNA sequence is expressed in or by a cell to form an "expression product" such as a protein. The expression product itself, e.g. the resulting protein, may also be said to be "expressed" by the cell.

10 The term "transfection" means the introduction of a foreign nucleic acid into a cell. The term "transformation" means the introduction of a "foreign" (i.e. extrinsic or extracellular) gene, DNA or RNA sequence to a host cell, so that the host cell will express the introduced gene or sequence to produce a desired substance, typically a protein or enzyme coded by the  
15 introduced gene or sequence. The introduced gene or sequence may also be called a "cloned", "foreign", or "heterologous" gene or sequence, and may include regulatory or control sequences used by a cell's genetic machinery. The gene or sequence may include nonfunctional sequences or sequences with no known function. A host cell that receives and expresses introduced  
20 DNA or RNA has been "transformed" and is a "transformant" or a "clone." The DNA or RNA introduced to a host cell can come from any source, including cells of the same genus or species as the host cell, or cells of a different genus or species.

The terms "vector", "cloning vector" and "expression vector"  
25 mean the vehicle by which a DNA or RNA sequence (e.g., a foreign gene) can be introduced into a host cell, so as to transform the host and promote expression (e.g., transcription and translation) of the introduced sequence. Vectors include plasmids, phages, viruses, etc. A "cassette" refers to a DNA coding sequence or segment of DNA that codes for an expression product  
30 that can be inserted into a vector at defined restriction sites. The cassette restriction sites are designed to ensure insertion of the cassette in the proper reading frame. Generally, foreign DNA is inserted at one or more restriction sites of the vector DNA, and then is carried by the vector into a host cell along with the transmissible vector DNA. A segment or sequence of DNA having  
35 inserted or added DNA, such as an expression vector, can also be called a "DNA construct." Recombinant cloning vectors will often include one or more

replication systems for cloning or expression, one or more markers for selection in the host, e.g. antibiotic resistance, and one or more expression cassettes.

- A "knockout mammal" is a mammal (e.g., mouse) that contains within its genome a specific gene that has been inactivated by the method of gene targeting (see, e.g., US Patents No. 5,777,195 and No. 5,616,491). A knockout mammal includes both a heterozygote knockout (i.e., one defective allele and one wild-type allele) and a homozygous mutant. Preparation of a knockout mammal requires first introducing a nucleic acid construct that will be used to suppress expression of a particular gene into an undifferentiated cell type termed an embryonic stem cell. This cell is then injected into a mammalian embryo. A mammalian embryo with an integrated cell is then implanted into a foster mother for the duration of gestation. Zhou, *et al.* (Genes and Development, 9:2623-34, 1995) describes PPCA knock-out mice. Knockout mice can be used to study defects in neurological development or neurodegenerative diseases. Disease phenotypes that develop can provide a platform for further drug discovery.

- The term "knockout" refers to partial or complete suppression of the expression of at least a portion of a protein encoded by an endogenous DNA sequence in a cell. The term "knockout construct" refers to a nucleic acid sequence that is designed to decrease or suppress expression of a protein encoded by endogenous DNA sequences in a cell. The nucleic acid sequence used as the knockout construct is typically comprised of (1) DNA from some portion of the gene (exon sequence, intron sequence, and/or promoter sequence) to be suppressed and (2) a marker sequence used to detect the presence of the knockout construct in the cell. The knockout construct is inserted into a cell, and integrates with the genomic DNA of the cell in such a position so as to prevent or interrupt transcription of the native DNA sequence. Such insertion usually occurs by homologous recombination (i.e., regions of the knockout construct that are homologous to endogenous DNA sequences hybridize to each other when the knockout construct is inserted into the cell and recombine so that the knockout construct is incorporated into the corresponding position of the endogenous DNA). The knockout construct nucleic acid sequence may comprise 1) a full or partial sequence of one or more exons and/or introns of the gene to be suppressed, 2) a full or partial promoter sequence of the gene to be suppressed, or 3) combinations thereof.

Typically, the knockout construct is inserted into an embryonic stem cell (ES cell) and is integrated into the ES cell genomic DNA, usually by the process of homologous recombination. This ES cell is then injected into, and integrates with, the developing embryo.

5 Generally, for homologous recombination, the DNA will be at least about 1 kilobase (kb) in length and preferably 3-4 kb in length, thereby providing sufficient complementary sequence for recombination when the knockout construct is introduced into the genomic DNA of the ES cell.

10 A "knock-in" mammal is a mammal in which an endogenous gene is substituted with a heterologous gene or a modified variant of the endogenous gene (Roemer *et al.*, New Biol. 3:331, 1991). Preferably, the heterologous gene is "knocked-in" to a locus of interest, for example into a gene that is the subject of evaluation of expression or function, thereby linking the heterologous gene expression to transcription from the appropriate  
15 promoter (in which case the gene may be a reporter gene; see Elefanty *et al.*, Proc Natl Acad Sci USA 95:11897,1998). This can be achieved by homologous recombination, transposon (Westphal and Leder, Curr Biol 7:530, 1997), using mutant recombination sites (Araki *et al.*, Nucleic Acids Res 25:868, 1997) or PCR (Zhang and Henderson, Biotechniques 25:784, 1998).<sup>5</sup>

20 The phrases "disruption of the gene" and "gene disruption" refer to insertion of a nucleic acid sequence into one region of the native DNA sequence (usually one or more exons) and/or the promoter region of a gene so as to decrease or prevent expression of that gene in the cell as compared to the wild-type or naturally occurring sequence of the gene. By way of  
25 example, a nucleic acid construct can be prepared containing a DNA sequence encoding an antibiotic resistance gene which is inserted into the DNA sequence that is complementary to the DNA sequence (promoter and/or coding region) to be disrupted. When this nucleic acid construct is then transfected into a cell, the construct will integrate into the genomic DNA.  
30 Thus, some progeny of the cell will no longer express the gene, or will express it at a decreased level, as the DNA is now disrupted by the antibiotic resistance gene.

The term "heterologous" refers to a combination of elements not naturally occurring. For example, heterologous DNA refers to DNA not  
35 naturally located in the cell, or in a chromosomal site of the cell. Preferably, the heterologous DNA includes a gene foreign to the cell. A heterologous

expression regulatory element is a such an element operatively associated with a different gene than the one it is operatively associated with in nature. In the context of the present invention, an gene is heterologous to the recombinant vector DNA in which it is inserted for cloning or expression, and it is heterologous to a host cell containing such a vector, in which it is expressed, e.g., a CHO cell.

The terms "mutant" and "mutation" mean any detectable change in genetic material, e.g. DNA, or any process, mechanism, or result of such a change. This includes gene mutations, in which the structure (e.g., DNA sequence) of a gene is altered, any gene or DNA arising from any mutation process, and any expression product (e.g., protein) expressed by a modified gene or DNA sequence. The term "variant" may also be used to indicate a modified or altered gene, DNA sequence, enzyme, cell, etc., i.e., any kind of mutant.

"Sequence-conservative variants" of a polynucleotide sequence are those in which a change of one or more nucleotides in a given codon position results in no alteration in the amino acid encoded at that position.

"Function-conservative variants" are those in which a given amino acid residue in a protein or enzyme has been changed without altering the overall conformation and function of the polypeptide, including, but not limited to, replacement of an amino acid with one having similar properties (such as, for example, polarity, hydrogen bonding potential, acidic, basic, hydrophobic, aromatic, and the like). Amino acids with similar properties are well known in the art. For example, arginine, histidine and lysine are hydrophilic-basic amino acids and may be interchangeable. Similarly, isoleucine, a hydrophobic amino acid, may be replaced with leucine, methionine or valine. Such changes are expected to have little or no effect on the apparent molecular weight or isoelectric point of the protein or polypeptide. Amino acids other than those indicated as conserved may differ in a protein or enzyme so that the percent protein or amino acid sequence similarity between any two proteins of similar function may vary and may be, for example, from 70% to 99% as determined according to an alignment scheme such as by the Cluster Method, wherein similarity is based on the MEGALIGN algorithm. A "function-conservative variant" also includes a polypeptide or enzyme which has at least 60 % amino acid identity as determined by BLAST (Altschul SF, *et al.*, J Mol Biol 1990; 215: 403-410) or

FASTA algorithms, preferably at least 75%, most preferably at least 85%, and even more preferably at least 90%, and which has the same or substantially similar properties or functions as the native or parent protein or enzyme to which it is compared.

- 5 An "ortholog" to a protein means a corresponding protein from another species. Orthologous proteins typically have similar functions in different species, and can also be substantially homologous.

- As used herein, the term "homologous" in all its grammatical forms and spelling variations refers to the relationship between proteins that  
10 possess a "common evolutionary origin," including proteins from superfamilies (e.g., the immunoglobulin superfamily) and homologous proteins from different species (e.g., myosin light chain, etc.) (Reeck *et al.*, Cell 50:667, 1987). Such proteins (and their encoding genes) have sequence homology, as reflected by their sequence similarity, whether in terms of percent similarity  
15 or the presence of specific residues or motifs. Motif analysis can be performed using, for example, the program BLOCKS ([www.blocks.fhcrc.org](http://www.blocks.fhcrc.org)).

- Accordingly, the term "sequence similarity" in all its grammatical forms refers to the degree of identity or correspondence between nucleic acid or amino acid sequences of proteins that may or may not share a common  
20 evolutionary origin (see Reeck *et al.*, *supra*). However, in common usage and in the instant application, the term "homologous," when modified with an adverb such as "highly," may refer to sequence similarity and may or may not relate to a common evolutionary origin.

- In a specific embodiment, two DNA sequences are "substantially  
25 homologous" or "substantially similar" when at least about 80%, and most preferably at least about 90 or 95% of the nucleotides match over the defined length of the DNA sequences, as determined by sequence comparison algorithms, such as BLAST, FASTA, DNA Strider, etc. Sequences that are substantially homologous can be identified by comparing the sequences using  
30 standard software available in sequence data banks, or in a Southern hybridization experiment under, for example, stringent conditions as defined for that particular system.

- Similarly, in a particular embodiment, two amino acid sequences are "substantially homologous" or "substantially similar" when greater than  
35 80% of the amino acids are identical, or greater than about 90% are similar (functionally identical). Preferably, the similar or homologous sequences are

identified by alignment using, for example, the GCG (Genetics Computer Group, Program Manual for the GCG Package, Version 7, Madison, Wisconsin) pileup program, ProteinPredict (dodo.cmpc.columbia.edu/predictprotein), or any of the programs described above (BLAST, FASTA, etc.).

A nucleic acid molecule is "hybridizable" to another nucleic acid molecule, such as a cDNA, genomic DNA, or RNA, when a single stranded form of the nucleic acid molecule can anneal to the other nucleic acid molecule under the appropriate conditions of temperature and solution ionic strength (see Sambrook *et al.*, *supra*). The conditions of temperature and ionic strength determine the "stringency" of the hybridization. For preliminary screening for homologous nucleic acids, low stringency hybridization conditions, corresponding to a  $T_m$  (melting temperature) of 55°C, can be used. Moderate stringency hybridization conditions correspond to a higher  $T_m$  and high stringency hybridization conditions correspond to the highest  $T_m$ . Hybridization requires that the two nucleic acids contain complementary sequences, although depending on the stringency of the hybridization, mismatches between bases are possible. The appropriate stringency for hybridizing nucleic acids depends on the length of the nucleic acids and the degree of complementation, variables well known in the art. The greater the degree of similarity or homology between two nucleotide sequences, the greater the value of  $T_m$  for hybrids of nucleic acids having those sequences. The relative stability (corresponding to higher  $T_m$ ) of nucleic acid hybridizations decreases in the following order: RNA:RNA, DNA:RNA, DNA:DNA. For hybrids of greater than 100 nucleotides in length, equations for calculating  $T_m$  have been derived (see Sambrook *et al.*, *supra*, 9.50-9.51). For hybridization with shorter nucleic acids, *i.e.*, oligonucleotides, the position of mismatches becomes more important, and the length of the oligonucleotide determines its specificity (see Sambrook *et al.*, *supra*, 11.7-11.8). A minimum length for a hybridizable nucleic acid is at least about 10 nucleotides; preferably at least about 15 nucleotides; and more preferably the length is at least about 20 nucleotides.

The present invention provides antisense nucleic acids (including ribozymes), which may be used to inhibit expression of PAMP, *e.g.*, to disrupt a cellular process (such disruption can be used in an animal model or therapeutically). An "antisense nucleic acid" is a single stranded nucleic

acid molecule which, on hybridizing under cytoplasmic conditions with complementary bases in an RNA or DNA molecule, inhibits the latter's role. If the RNA is a messenger RNA transcript, the antisense nucleic acid is a countertranscript or mRNA-interfering complementary nucleic acid. As presently used, "antisense" broadly includes RNA-RNA interactions, RNA-DNA interactions, ribozymes and RNase-H mediated arrest. Antisense nucleic acid molecules can be encoded by a recombinant gene for expression in a cell (e.g., U.S. Patent No. 5,814,500; U.S. Patent No. 5,811,234), or alternatively they can be prepared synthetically (e.g., U.S. Patent No. 5,780,607).

As used herein, the term "oligonucleotide" refers to a nucleic acid, generally of at least 10, preferably at least 15, and more preferably at least 20 nucleotides, preferably no more than 100 nucleotides, that is hybridizable to a genomic DNA molecule, a cDNA molecule, or an mRNA molecule encoding a gene, mRNA, cDNA, or other nucleic acid of interest. Oligonucleotides can be labeled, e.g., with  $^{32}\text{P}$ -nucleotides or nucleotides to which a label, such as biotin, has been covalently conjugated. In one embodiment, a labeled oligonucleotide can be used as a probe to detect the presence of a nucleic acid. In another embodiment, oligonucleotides (one or both of which may be labeled) can be used as PCR primers, e.g., for cloning full length or a fragment of a protein or polypeptide. In a further embodiment, an oligonucleotide of the invention can form a triple helix with a nucleic acid (genomic DNA or mRNA) encoding a protein or polypeptide. Generally, oligonucleotides are prepared synthetically, preferably on a nucleic acid synthesizer. Accordingly, oligonucleotides can be prepared with non-naturally occurring phosphoester analog bonds, such as thioester bonds, etc. Furthermore, the oligonucleotides herein may also be modified with a label capable of providing a detectable signal, either directly or indirectly. Exemplary labels include radioisotopes, fluorescent molecules, biotin, and the like.

Specific non-limiting examples of synthetic oligonucleotides envisioned for this invention include oligonucleotides that contain phosphorothioates, phosphotriesters, methyl phosphonates, short chain alkyl, or cycloalkyl intersugar linkages or short chain heteroatomic or heterocyclic intersugar linkages. Most preferred are those with  $\text{CH}_2\text{-NH-O-CH}_2$ ,  $\text{CH}_2\text{-N(CH}_3\text{)-O-CH}_2$ ,  $\text{CH}_2\text{-O-N(CH}_3\text{)-CH}_2$ ,  $\text{CH}_2\text{-N(CH}_3\text{)-N(CH}_3\text{)-CH}_2$  and  $\text{O-N(CH}_3\text{)-}$

CH<sub>2</sub>-CH<sub>2</sub> backbones (where phosphodiester is O-PO<sub>2</sub>-O-CH<sub>2</sub>). US Patent No. 5,677,437 describes heteroaromatic oligonucleoside linkages. Nitrogen linkers or groups containing nitrogen can also be used to prepare oligonucleotide mimics (U.S. Patents No. 5,792,844 and No. 5,783,682). US Patent No. 5,637,684 describes phosphoramidate and phosphorothioamidate oligomeric compounds. Also envisioned are oligonucleotides having morpholino backbone structures (U.S. Pat. No. 5,034,506). In other embodiments, such as the peptide-nucleic acid (PNA) backbone, the phosphodiester backbone of the oligonucleotide may be replaced with a polyamide backbone, the bases being bound directly or indirectly to the aza nitrogen atoms of the polyamide backbone (Nielsen *et al.*, Science 254:1497, 1991). Other synthetic oligonucleotides may contain substituted sugar moieties comprising one of the following at the 2' position: OH, SH, SCH<sub>3</sub>, F, OCN, O(CH<sub>2</sub>)<sub>n</sub>NH<sub>2</sub> or O(CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub> where n is from 1 to about 10; C<sub>1</sub> to C<sub>10</sub> lower alkyl, substituted lower alkyl, alkaryl or aralkyl; Cl; Br; CN; CF<sub>3</sub>; OCF<sub>3</sub>; O-; S-, or N-alkyl; O-, S-, or N-alkenyl; SOCH<sub>3</sub>; SO<sub>2</sub>CH<sub>3</sub>; ONO<sub>2</sub>; NO<sub>2</sub>; N<sub>3</sub>; NH<sub>2</sub>; heterocycloalkyl; heterocycloalkaryl; aminoalkylamino; polyalkylamino; substituted silyl; a fluorescein moiety; an RNA cleaving group; a reporter group; an intercalator; a group for improving the pharmacokinetic properties of an oligonucleotide; or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. Oligonucleotides may also have sugar mimetics such as cyclobutyls or other carbocyclics in place of the pentofuranosyl group. Nucleotide units having nucleosides other than adenosine, cytidine, guanosine, thymidine and uridine, such as inosine, may be used in an oligonucleotide molecule.

#### Presenilin Interacting Proteins

Mutant PS1 and PS2 genes, and their corresponding amino acid sequences are described in Applicants' co-pending U.S. Application Serial No. 08/888,077, filed July 3, 1997, and incorporated herein by reference. Examples of PS1 mutations include I143T, M146L, L171P, F177S, A260V, C263R, P264L, P267S, E280A, E280G, A285V, L286V, Δ291-319, L322V, G384A, L392V, C410Y and I439V. Examples of PS2 mutations include N141I, M239V and I420T.

The methods of the present invention are not limited to mutant presenilins wherein the PAMP-interacting domain is mutated relative to the



wild-type protein. For example, Applicants have observed that mutations in PS1 (e.g., M146L) outside of the interacting domain (loop) also affect  $\beta$ -catenin translocation. These mutations probably disturb the presenilin *armadillo* interactions by altering the function of a high MW complex which contains, e.g., the presenilin and *armadillo* proteins, as described in Yu *et al.*, 1998, *J. Biol. Chem.* 273:16460-16475. Moreover, a comparison of the human PS1 (hPS1) and PS2 (hPS2) sequences reveals that these pathogenic mutations are in regions of the PS1 protein which are conserved in the PS2 protein. Therefore, corresponding mutations in corresponding regions of PS2 may also be expected to be pathogenic and are useful in the methods described herein.

Proteins that interact with the presenilins, i.e., PS-interacting proteins, include PAMP, the S5a subunit of the 26S proteasome (GenBank; Accession No. U51007), Rab11 (GenBank; Accession Nos. X56740 and X53143), retinoid X receptor B, also known as nuclear receptor co-regulator or MHC (GenBank Accession Nos. M84820, and X63522), GT24 (GenBank Accession No. U81004),  $\beta$ -catenin (Zhou *et al.*, 1997, *Neuro. Report* (Fast Track) 8:1025-1029 and Yu *et al.*, *supra*) as well as *armadillo* proteins. These and other PS1 binding proteins are described in Applicants' copending commonly assigned U.S. Application Serial No. 08/833,077, filed July 3, 1997, as well as U.S. Application Serial No. 08/592,541, filed January 26, 1996, the disclosures of which are incorporated herein by reference.

#### PAMP Mutants

PAMP mutants may cause biochemical changes similar to those affecting the onset or progression of Alzheimer Disease. Therefore, artificial PAMP mutations can potentially be used to generate cellular and other model systems to design treatments and preventions for Alzheimer Disease related disorders. Such mutations may also be used for evaluating whether PAMP is involved in the pathogenesis of AD. Since the amyloid- $\beta$  ( $A\beta$ ) inducing mutations are found in amino acid residues of a soluble (non-membrane spanning) domain of PAMP, analysis of the normal structure of this domain and the effects of these and other nearby mutations on the structure of this domain (and the other domains of PAMP) provide information for the design of specific molecular therapeutics.

- In general, modifications of the sequences encoding the polypeptides described herein may be readily accomplished by standard techniques such as chemical syntheses and site-directed mutagenesis. See Gillman *et al.*, 1979, *Gene* 8:81-97; Roberts *et al.*, 1987, *Nature* 328:731-734; and Innis (ed.), 1990, *PCR Protocols: A Guide to Methods and Applications*, Academic Press, New York. Most modifications are evaluated by routine screening via an assay designed to select for the desired property.

#### Antibodies to PAMP

- According to the invention, PAMP polypeptides produced recombinantly or by chemical synthesis, and fragments or other derivatives or analogs thereof, including fusion proteins and PAMP mutants, may be used as an immunogen to generate antibodies that recognize the PAMP polypeptide. Such antibodies include but are not limited to polyclonal, monoclonal, chimeric, single chain, Fab fragments, and an Fab expression library. Such an antibody is preferably specific for human PAMP, PAMP originating from other species, or for post-translationally modified (e.g. phosphorylated, glycosylated) PAMP.
- Various procedures known in the art may be used for the production of polyclonal antibodies to PAMP polypeptide or derivative or analog thereof. For the production of antibody, various host animals can be immunized by injection with the PAMP polypeptide, or a derivative (e.g., fragment or fusion protein) thereof, including but not limited to rabbits, mice, rats, sheep, goats, etc. In one embodiment, the PAMP polypeptide or fragment thereof can be conjugated to an immunogenic carrier, e.g., bovine serum albumin (BSA) or keyhole limpet hemocyanin (KLH). Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (*bacille Calmette-Guerin*) and *Corynebacterium parvum*. Antisera may be collected at a chosen time point after immunization, and purified as desired.
- For preparation of monoclonal antibodies directed toward the PAMP polypeptide, or fragment, analog, or derivative thereof, any technique

According to the invention, techniques described for the production of single chain antibodies (U.S. Patent Nos. 5,476,786 and 5,132,405 to Huston; U.S. Patent 4,946,778) can be adapted to produce PAMP polypeptide-specific single chain antibodies. An additional 30 embodiment of the invention utilizes the techniques described for the construction of Fab expression libraries (Huse *et al.*, Science 246:1275-1281, 1989) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity for a PAMP polypeptide, or its derivatives, or analogs.

Antibody fragments which contain the idiotype of the antibody  
35 molecule can be generated by known techniques. For example, such  
fragments include but are not limited to: the F(ab')<sub>2</sub> fragment which can be

produced by pepsin digestion of the antibody molecule; the Fab' fragments which can be generated by reducing the disulfide bridges of the F(ab')<sub>2</sub> fragment, and the Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent.

- 5 In the production of antibodies, screening for the desired antibody can be accomplished by techniques known in the art, e.g., radioimmunoassay, ELISA (enzyme-linked immunosorbent assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitin reactions, immunodiffusion assays, *in situ* immunoassays (using colloidal  
10 gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary  
15 antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention. For example, to select antibodies which  
20 recognize a specific epitope of an PAMP polypeptide, one may assay generated hybridomas for a product which binds to an PAMP polypeptide fragment containing such epitope. For selection of an antibody specific to an PAMP polypeptide from a particular species of animal, one can select on the basis of positive binding with PAMP polypeptide expressed by or isolated from  
25 cells of that species of animal.

- The foregoing antibodies can be used in methods known in the art relating to the localization and activity of the PAMP polypeptide, e.g., for Western blotting, imaging PAMP polypeptide *in situ*, measuring levels thereof in appropriate physiological samples, etc. using any of the detection  
30 techniques mentioned above or known in the art. Such antibodies can be used to identify proteins that interact with PAMP, and to detect conformational or structural changes in PAMP.

- In a specific embodiment, antibodies that agonize or antagonize the activity of PAMP polypeptide can be generated. They can also be used to  
35 regulate or inhibit PAMP activity intracellular, i.e., the invention contemplates an intracellular antibody (intrabody), e.g., single chain Fv antibodies (see

generally, Chen, Mol. Med. Today, 3:160-167, 1997; Spitz *et al.*, Anticancer Res., 16:3415-3422, 1996; Indolfi *et al.*, Nat. Med., 2:634-635, 1996; Kijima *et al.*, Pharmacol. Ther., 68:247-267, 1995).

5 **PAMP Diagnostic Assays**

The nucleotide sequence and the protein sequence and the putative biological activity of PAMP or PAMP mutants can all be used for the purposes of diagnosis of individuals who are at-risk for, or who actually have, a variety of neurodegenerative diseases (including Alzheimer's disease, Lewy  
10 body variant, Parkinson's disease-dementia complex, amyotrophic lateral sclerosis etc.), neuropsychiatric diseases (schizophrenia, depression, mild cognitive impairment, benign senescent forgetfulness, age-associated memory loss, etc.), developmental disorders associated with defects in intracellular signal transduction mediated by factors such as Notch, Delta,  
15 Wingless, etc., and neoplasms (e.g., bowel cancer, etc.) associated with abnormalities of PS1/PAMP/PS2 mediated regulation of cell death pathways. These diagnostic entities can be used by searching for alterations in: the nucleotide sequence of PAMP; in the transcriptional activity of PAMP; in the protein level as monitored by immunological means (e.g., ELISA and Western  
20 blots); in the amino acid sequence (as ascertained by Western blotting, amino acid sequence analysis, mass spectroscopy); and/or in the biological activity of the PAMP protein as measured by either *in vivo* methods (e.g., monitoring  $\beta$ APP processing and the production of amyloid- $\beta$  peptide (A $\beta$ ), or other suitable protein substrates for PAMP including Notch, etc.), or by *in vitro*  
25 assays (using either whole cell or cell-free assays to measure processing of suitable substrates including  $\beta$ APP or parts thereof, and other proteins such as Notch). Any of these assays can also be performed in a transgenic animal model as well, e.g., to measure the effect of a drug or a mutation or overexpression of a different gene *in vivo*.

30

**PAMP Screening Assays**

Identification and isolation of PAMP provides for development of screening assays, particularly for high throughput screening of molecules that up- or down-regulate the activity of PAMP, e.g., by permitting expression of  
35 PAMP in quantities greater than can be isolated from natural sources, or in indicator cells that are specially engineered to indicate the activity of PAMP

expressed after transfection or transformation of the cells. Any screening technique known in the art can be used to screen for PAMP agonists or antagonists. The present invention contemplates screens for small molecule ligands or ligand analogs and mimics, as well as screens for natural ligands that bind to and agonize or antagonize the activity of PAMP *in vivo*. For example, natural products libraries can be screened using assays of the invention for molecules that agonize or antagonize PAMP activity.

Another approach uses recombinant bacteriophage to produce large libraries. Using the "phage method" (Scott and Smith, Science 249:386-390, 1990; Cwirla, *et al.*, Proc. Natl. Acad. Sci., 87:6378-6382, 1990; Devlin *et al.*, Science, 49:404-406, 1990), very large libraries can be constructed ( $10^6$ - $10^8$  chemical entities). A second approach uses primarily chemical methods, of which the Geysen method (Geysen *et al.*, Molecular Immunology 23:709-715, 1986; Geysen *et al.* J. Immunologic Method 102:259-274, 1987; and the method of Fodor *et al.* (Science 251:767-773, 1991) are examples. Furka *et al.* (14th Int. Congress of Biochemistry, Volume 5, Abstract FR:013, 1988; Furka, Int. J. Peptide Protein Res. 37:487-493, 1991), Houghton (U.S. Patent No. 4,631,211, issued December 1986) and Rutter *et al.* (U.S. Patent No. 5,010,175, issued April 23, 1991) describe methods to produce a mixture of peptides that can be tested as agonists or antagonists.

In another aspect, synthetic libraries (Needels *et al.*, Proc. Natl. Acad. Sci. USA 90:10700-4, 1993; Ohlmeyer *et al.*, Proc. Natl. Acad. Sci. USA 90:10922-10926, 1993; Lam *et al.*, International Patent Publ. No. WO 92/00252; Kocis *et al.*, International Patent Publ. No. WO 9428028) and the like can be used to screen for PAMP ligands according to the present invention.

Knowledge of the primary sequence of the protein, and the similarity of that sequence with proteins of known function, can provide an initial clue as to the inhibitors or antagonists of the protein. As noted above, identification and screening of antagonists is further facilitated by determining structural features of the protein, e.g., using X-ray crystallography, neutron diffraction, nuclear magnetic resonance spectrometry, and other techniques for structure determination. These techniques provide for the rational design or identification of agonists and antagonists.

The PAMP protein sequence (including parts thereof) can be used to deduce the structural organization and topology of PAMP through the

use of a variety of techniques including CD spectroscopy, nuclear magnetic resonance (NMR) spectroscopy, X-ray crystallography, and molecular modeling. Sequences for PAMP or PAMP mutants can also be used to identify proteins which interact with PAMP either in concert with PS1 and PS2, or independently, using a variety of methods including co-immunoprecipitation, yeast two hybrid interaction trap assays, yeast three hybrid interaction trap assays, chemical cross-linking and co-precipitation studies, etc. These and other methods are described more fully in co-pending and commonly assigned U.S. Application Serial No. 08/888,077, filed July 3, 1997, and 09/227,725, filed January 8, 1999, both of which are incorporated herein by reference. Identification of these interacting partners will then lead to their use to further delineate the biochemical pathways leading to the above-mentioned diseases.

Finally, the structural analysis of PAMP, when combined with structural analysis of PS1 and PS2, and other proteins which interact with PAMP or PAMP mutants, will identify the structural domains that mediate interactions between these molecules and which also confer biological activity on PAMP (or PAMP and these other molecules). These structural domains, and other functional domains, which can modulate the activity of these structural domains, can all be modified through a variety of means, including but not limited to site-directed mutagenesis, in order to either augment or reduce the biological activity. The structure and topology of these domains can all be used as a basis for the rational design of pharmaceuticals (small molecule conventional drugs or novel carbohydrate, lipid, DNA/RNA or protein-based high molecular weight biological compounds) to modulate (increase or decrease) the activity of PAMP and/or the PAMP PS1/PS2 complex, and/or the activity of the PAMP/other protein complexes. For example, using structural prediction calculations, possibly in conjunction with spectroscopic data like nuclear magnetic resonance, circular dichroism, and other physical-chemical structural data, or crystallographic data, or both, one can generate molecular models for the structure of PAMP. These models, in turn, are important for rational drug design. Drug candidates generated using a rational drug design program can then be applied for the treatment and/or prevention of the above-mentioned diseases, and can be administered through a variety of means including: as conventional small molecules through enteral or parenteral routes; via inclusion in liposome vehicles;

5

## 15

20

30



Regulated knockout animals can be prepared using various systems, such as the tet-repressor system (see US Patent No. 5,654,168) or the Cre-Lox system (see US Patents No. 4,959,317 and No. 5,801,030).

Transgenic mammals can be prepared for evaluating the molecular mechanisms of PAMP, and particularly human PAMP/PS1 or PAMP/PS2 function. Such mammals provide excellent models for screening or testing drug candidates. It is possible to evaluate compounds or diseases on "knockout" animals, e.g., to identify a compound that can compensate for a defect in PAMP activity. Alternatively, PAMP (or mutant PAMP), alone or in combination with  $\beta$ APP, PS1, and/or PS2, (double or triple transgenics) "knock-in" mammals can be prepared for evaluating the molecular biology of this system in greater detail than is possible with human subjects. Both technologies permit manipulation of single units of genetic information in their natural position in a cell genome and to examine the results of that manipulation in the background of a terminally differentiated organism. These animals can be evaluated for levels of mRNA or protein expression, processing of  $\beta$ APP, or development of a condition indicative of inappropriate gene expression, e.g., *Notch* phenotype or another phenotype as set forth above, or neurodegeneration, including cognitive deficits, learning or memory deficits, or neuromuscular deficits.

Various transgenic animal systems have been developed. Mice, rats, hamsters, and other rodents are popular, particularly for drug testing, because large numbers of transgenic animals can be bred economically and rapidly. Larger animals, including sheep, goats, pigs, and cows, have been made transgenic as well. Transgenic *D.melanogaster* and *C.elegans* can also be made and, using known genetic methods, may offer the ability to identify upstream and downstream modifiers of a PAMP phenotype. Transgenic animals can also be prepared by introducing the transgene on a vector; such animals, which are not modified in the germ line and are only transiently transgenic, naturally cannot pass along the genetic information to their progeny.

In another series of embodiments, transgenic animals are created in which (i) a human PAMP, or a mutant human PAMP, is stably inserted into the genome of the transgenic animal; and/or (ii) the endogenous PAMP genes are inactivated and replaced with their human counterparts. See, e.g., Coffman, Semin. Nephrol. 17:404, 1997; Esther *et al.*, Lab. Invest.

74:953, 1996; Murakami *et al.*, Blood Press. Suppl. 2:36, 1996. Such animals can be treated with candidate compounds and monitored for the effects of such drugs on PAMP cavity.

5

#### PAMP Gene Therapy

As discussed above, abnormalities in PAMP expression and/or interactions with PS1/PS2/ $\beta$ APP are associated with severe neurological deficits. Thus, the present invention provides for treatment of such deficits either with a drug discovered using a screening assay or transgenic animal  
10 model, or both, as set forth above, or by replacing a defective *PAMP* gene with a functional gene by gene therapy.

A gene encoding PAMP, a PAMP mutant, or alternatively a negative regulator of PAMP such as an antisense nucleic acid, intracellular antibody (intrabody), or dominant negative PAMP (which may be truncated), can be introduced *in vivo*, *ex vivo*, or *in vitro* using a viral or a non-viral vector,  
15 e.g., as discussed above. Expression in targeted tissues can be effected by targeting the transgenic vector to specific cells, such as with a viral vector or a receptor ligand, or by using a tissue-specific promoter, or both. Targeted gene delivery is described in International Patent Publication WO 95/28494,  
20 published October 1995.

Preferably, for *in vivo* administration, an appropriate immunosuppressive treatment is employed in conjunction with the viral vector, e.g., adenovirus vector, to avoid immuno-deactivation of the viral vector and transfected cells. For example, immunosuppressive cytokines, such as  
25 interleukin 12 (IL-12), interferon- $\gamma$  (IFN $\gamma$ ), or anti-CD4 antibody, can be administered to block humoral or cellular immune responses to the viral vectors (see, e.g., Wilson, Nature Medicine, 1995). In that regard, it is advantageous to employ a viral vector that is engineered to express a minimal number of antigens.

30 ***Herpes virus vectors.*** Because herpes virus is trophic for cells of the nervous system (neural cells), it is an attractive vector for delivery of function *PAMP* genes. Various defective (non-replicating, and thus non-infectious) herpes virus vectors have been described, such as a defective herpes virus 1 (HSV1) vector (Kapliitt *et al.*, Molec. Cell. Neurosci. 2:320-330,  
35 1991; International Patent Publication No. WO 94/21807, published

September 29, 1994; International Patent Publication No. WO 92/05263, published April 2, 1994).

**Adenovirus vectors.** Adenoviruses are eukaryotic DNA viruses that can be modified to efficiently deliver a nucleic acid of the invention to a variety of cell types *in vivo*, and has been used extensively in gene therapy protocols, including for targeting genes to neural cells. Various serotypes of adenovirus exist. Of these serotypes, preference is given to using type 2 or type 5 human adenoviruses (Ad 2 or Ad 5) or adenoviruses of animal origin (see WO94/26914). Those adenoviruses of animal origin which can be used within the scope of the present invention include adenoviruses of canine, bovine, murine (example: Mav1, Beard *et al.*, Virology 75 (1990) 81), ovine, porcine, avian, and simian (example: SAV) origin. Preferably, the adenovirus of animal origin is a canine adenovirus, more preferably a CAV2 adenovirus (e.g., Manhattan or A26/61 strain (ATCC VR-800), for example). Various replication defective adenovirus and minimum adenovirus vectors have been described for gene therapy (WO94/26914, WO95/02697, WO94/28938, WO94/28152, WO94/12649, WO95/02697 WO96/22378). The replication defective recombinant adenoviruses according to the invention can be prepared by any technique known to the person skilled in the art (Levero *et al.*, Gene 101:195 1991; EP 185 573; Graham, EMBO J. 3:2917, 1984; Graham *et al.*, J. Gen. Virol. 36:59 1977). Recombinant adenoviruses are recovered and purified using standard molecular biological techniques, which are well known to one of ordinary skill in the art.

**Adeno-associated viruses.** The adeno-associated viruses (AAV) are DNA viruses of relatively small size which can integrate, in a stable and site-specific manner, into the genome of the cells which they infect. They are able to infect a wide spectrum of cells without inducing any effects on cellular growth, morphology or differentiation, and they do not appear to be involved in human pathologies. The AAV genome has been cloned, sequenced and characterized. The use of vectors derived from the AAVs for transferring genes *in vitro* and *in vivo* has been described (see WO 91/18088; WO 93/09239; US 4,797,368, US 5,139,941, EP 488 528). The replication defective recombinant AAVs according to the invention can be prepared by co-transfecting a plasmid containing the nucleic acid sequence of interest flanked by two AAV inverted terminal repeat (ITR) regions, and a plasmid carrying the AAV encapsidation genes (rep and cap genes), into a cell line

**Retrovirus vectors.** In another embodiment the gene can be

Retrovirus vectors can also be introduced by recombinant DNA

**Lentivirus vectors.** In another embodiment, lentiviral vectors

SUBSTITUTE SHEET (RULE 26)

these tissues, and maintain long-term expression of the gene of interest. For a review, see, Naldini, Curr. Opin. Biotechnol., 9:457-63, 1998; see also Zufferey, *et al.*, J. Virol., 72:9873-80, 1998). Lentiviral packaging cell lines are available and known generally in the art. They facilitate the production of

5 high-titer lentivirus vectors for gene therapy. An example is a tetracycline-inducible VSV-G pseudotyped lentivirus packaging cell line which can generate virus particles at titers greater than 10<sup>6</sup> IU/ml for at least 3 to 4 days (Kafri, *et al.*, J. Virol., 73: 576-584, 1999). The vector produced by the inducible cell line can be concentrated as needed for efficiently transducing

10 nondividing cells *in vitro* and *in vivo*.

**Non-viral vectors.** A vector can be introduced *in vivo* in a non-viral vector, e.g., by lipofection, with other transfection facilitating agents (peptides, polymers, etc.), or as naked DNA. Synthetic cationic lipids can be used to prepare liposomes for *in vivo* transfection, with targeting in some

15 instances (Felgner, *et al.*, Proc. Natl. Acad. Sci. U.S.A. 84:7413-7417, 1987; Felgner and Ringold, Science 337:387-388, 1989; see Mackey, *et al.*, Proc. Natl. Acad. Sci. U.S.A. 85:8027-8031, 1988; Ulmer *et al.*, Science 259:1745-1748, 1993). Useful lipid compounds and compositions for transfer of nucleic acids are described in International Patent Publications WO95/18863 and

20 WO96/17823, and in U.S. Patent No. 5,459,127. Other molecules are also useful for facilitating transfection of a nucleic acid *in vivo*, such as a cationic oligopeptide (e.g., International Patent Publication WO95/21931), peptides derived from DNA binding proteins (e.g., International Patent Publication WO96/25508), or a cationic polymer (e.g., International Patent Publication

25 WO95/21931). Recently, a relatively low voltage, high efficiency *in vivo* DNA transfer technique, termed electroporation, has been described (Mir *et al.*, C.P. Acad. Sci., 321:893, 1998; WO 99/01157; WO 99/01158; WO 99/01175). DNA vectors for gene therapy can be introduced into the desired host cells by methods known in the art, e.g., electroporation, microinjection, cell fusion,

30 DEAE dextran, calcium phosphate precipitation, use of a gene gun (ballistic transfection), or use of a DNA vector transporter (see, e.g., Wu *et al.*, J. Biol. Chem. 267:963-967, 1992; Wu and Wu, J. Biol. Chem. 263:14621-14624, 1988; Hartmut *et al.*, Canadian Patent Application No. 2,012,311, filed March 15, 1990; Williams *et al.*, Proc. Natl. Acad. Sci. USA 88:2726-2730, 1991).

35 Receptor-mediated DNA delivery approaches can also be used (Curiel *et al.*, Hum. Gene Ther. 3:147-154, 1992; Wu and Wu, J. Biol. Chem. 262:4429-

4432, 1987). US Patent Nos. 5,580,859 and 5,589,466 disclose delivery of exogenous DNA sequences, free of transfection facilitating agents, in a mammal.

5

### EXAMPLES

The present invention will be further understood by reference to the following examples, which are provided as exemplary of the invention and not by way of limitation.

10 **EXAMPLE 1: A novel PAMP that mediates  $\beta$ APP processing and Notch/Glp1 signal transduction**

This example shows that both PS1 and PS2 interact with a novel Type I transmembrane protein, PAMP, and that this novel protein also interacts with  $\alpha$ - and  $\beta$ -secretase derived fragments of  $\beta$ APP. We also show that abolition of functional expression of the *C. elegans* homologue of the  
15 protein leads to a developmental phenotype (anterior pharynx 2 -*aph2*) which is thought to be due to inhibition of the *glp/Notch* signaling pathway. This novel protein is therefore positioned to mediate both the gain of function and loss of function phenotypes associated with presenilin missense mutations  
20 and presenilin knockouts, respectively.

### Materials and Methods

***Antibodies against PS1, PS2 and  $\beta$ APP.*** An antibody, termed 1142, directed against PS1, was raised to a peptide segment corresponding  
25 to residues 30-45 of PS1 (Levesque *et al.*, J Neurochem 1998: 72:999-1008; Yu *et al.*, Biol Chem 1998; 273:16470-16475). The peptide was synthesized by solid-phase techniques and purified by reverse phase high pressure liquid chromatography (HPLC). Peptide antigens were linked to keyhole limpet hemocyanin (KLH) and used, in combination with complete Freud's adjuvant,  
30 to inoculate New Zealand White rabbits. Antisera from three rabbits was pooled, ammonium precipitated and the antibody was purified with Suifo-link (Pierce) agarose-peptide affinity columns. Other antibodies used include antibody 369, a polyclonal rabbit-anti-human antibody directed against the C-terminus of human  $\beta$ APP (Buxbaum *et al.*, Proc. Natl. Acad. Sci. USA 1990;  
35 87: 6003-6007); antibody 14 (Ab14), a rabbit polyclonal antibody raised against residues 1-25 of human PS1 (Seeger *et al.*, Proc. Natl. Acad. Sci.

1997; 94: 5090-5094); antibody  $\alpha$ -PS1-CTF, a polyclonal rabbit antibody directed against the PS1 loop; and antibody DT2, a monoclonal antibody raised to a GST-fusion protein containing the PS2 N-terminal sequence from residues 1-87.

- 5        **Preparation of presenilin associated components.** To identify membrane associated components of the presenilin complex, an immunoaffinity procedure was used to extract PS1 and tightly associated membrane proteins from semi-purified intracellular membrane fractions. Human embryonic kidney cells (HEK) 293 (ATCC) with a stable over-  
10       expression of moderate level wild type human PS1, were grown to confluence, washed twice with ice-cold phosphate-buffered saline, and then homogenized with Buffer A (0.25 M sucrose, 20 mM HEPES pH 7.2, 2 mM EGTA, 2 mM EDTA, 1 mM DTT, and a protease inhibitor cocktail containing 5  
15        $\mu$ g/ml each of Leupeptin, Antipain, pepstatin A, Chymostatin, E64, Aprotinin, and 60  $\mu$ g/ml 4-(2-aminoethyl)-benzenesulfonyl fluoride (AEBSF)). The cell homogenates were centrifuged 1000 $\times$ g for 10 minutes to remove cell debris. The supernatant was then centrifuged 10,000 $\times$ g for 60 minutes. The resulting membrane pellet was resuspended in Buffer B (20 mM HEPES pH 7.2, 1 M  
20       KCl, 2 mM EGTA, 2 mM EDTA, 1 mM DTT, and protease inhibitor cocktail as above) and incubated for 45 minutes with agitation at 4°C. Cell membranes were collected again by centrifugation at 107,000  $\times$ g for 60 minutes. The cell membranes were then lysed on ice for 60 minutes with Buffer C (1% Digitonin, 20 mM HEPES pH 7.2, 100 mM KCl, 2 mM EGTA, 2 mM EDTA, 1  
25       mM DTT, and protease inhibitors cocktail). After spinning 10,000  $\times$  g for 15 minutes, the protein extract was adjusted with Buffer C to contain 5 mg/ml protein. A total of 0.5 g of protein was obtained.

- Isolation.** The extracted proteins were then subjected to fractionation with 10-40% glycerol gradient containing 0.5% Digitonin as described (Yu G, et al., J Biol Chem 1998; 273: 16470-16475). After being  
30       verified by Western blotting with anti-PS1 antibodies, the peak fractions containing PS1 were pooled and incubated overnight with Protein A/G agarose coupled with either antibody 1142 or a control IgG purified from preimmune rabbit serum. The Protein A/G agarose beads were washed three times with Buffer D (1% Digitonin, 20 mM HEPES pH 7.2, 100 mM KCl, protease inhibitors cocktail), and three times with Buffer E (0.5% Digitonin,  
35       0.5% CHAPS, 20 mM HEPES pH 7.2, 100 mM KCl, 10 mM  $\text{CaCl}_2$ , 5 mM

MgCl<sub>2</sub>, and the protease inhibitor cocktail as above). Isolated protein complexes were eluted from the beads with 0.1M Glycine-HCl, pH 3.0, and then neutralized with 1M Tris. Proteins were then separated by Tris-Glycine SDS-PAGE gels and stained with silver stain and Coomassie Blue stain. The staining of the immuno-purified proteins displayed two intense bands in addition to those of the presenilin holoprotein and its fragments.

**Sequence analysis.** Individual protein bands were cut out and analyzed with solid-phase extraction capillary electrophoresis mass spectrometry/mass spectrometry (SPE-CE-MS/MS). Briefly, protein bands were first digested in-gel with trypsin; the digested proteins were extracted and dried in a speed vacuum down to concentrate the peptides; and the peptides thereafter separated with micro LC and analyzed by on-line tandem mass spectrometry (Figgey *et al.*, Anal Chem 1999; 71: 2279-2287). Nucleotide and amino acid sequence homology searches were conducted using the BLAST algorithm, and motif analyses performed using the program BLOCKS.

**General transfection and analysis methods.** Based on the human PAMP sequence, public databases (e.g., GenBank; www.ncbi.nlm.nih.gov) were searched for homologous ESTs (SEQ ID NOs: 3-10), which were collected into a few contigs. These contigs all turned out to be correct, but did not cover full-length mouse and *D. melanogaster* cDNAs.

Full length murine (SEQ ID NO: 15), human (SEQ ID NO: 13) and *D. melanogaster* (SEQ ID NO: 17) PAMP cDNAs were obtained using oligonucleotides designed from partial cDNA/EST sequences in public databases to screen appropriate cDNA libraries, for 5'RACE, and/or for RT-PCR experiments. A PAMP expression construct was generated by inserting human PAMP cDNA in-frame with the V5 epitope of pcDNA6 (Invitrogen) at the C-terminus of PAMP. HEK293 cells with a stable expression of PS1/PS2 and  $\beta$ APP<sub>SW</sub> were transiently transfected with either V5-tagged PAMP or empty plasmid (mock transfection control). Duplicate experiments were performed by: (1) transient transfection of V5-PAMP and  $\beta$ APP<sub>895</sub> (or empty vector plus  $\beta$ APP<sub>895</sub> as a mock transfection control) into murine embryonic fibroblasts stably infected with human PS1 expressed from a retroviral vector construct (Clontech, CA); or (2) transient transfection of V5-PAMP (or an empty plasmid) into HEK293 cell lines with a stable expression of the C-terminal 99 amino acids of  $\beta$ APP with a preceding artificial signal peptide





(SEQ ID NO: 16) and *D.melanogaster* (SEQ ID NO: 18) orthologues of PAMP were cloned and examined. The four orthologous PAMP proteins had a similar topology and significant sequence conservation near residues 306-360, 419-458, and 625-662 of human PAMP (SEQ ID NO: 14) (Figure 1A and 1B). Motif analysis of these conserved domains revealed a weak similarity (strength = 1046) between residues 625 - 641 (ARLARALSPAFELSQWS; SEQ ID NO: 19) of mouse and human PAMP to cyclic nucleotide binding domains. While the putative transmembrane domain sequences were not highly conserved, all four orthologues contained a conserved serine residue within this hydrophobic domain. Finally, there were four conserved cysteine residues in the - terminal hydrophilic domain (Cys<sub>195</sub>, Cys<sub>213</sub>, Cys<sub>230</sub>, and Cys<sub>248</sub> in human PAMP) which had a periodicity of 16-17 residues in the N-terminus, and may form a functional domain (e.g., a metal binding domain or disulfide bridges for stabilizing the tertiary structure of PAMP/PAMP complexes).

**Interaction of PAMP with presenilin 1.** To confirm the authenticity of the PAMP:PS1 interaction, HEK293 cells were transiently transfected with PAMP cDNA (SEQ ID NO: 13) tagged at the 3'-end with a V5-epitope encoded from the pcDNA6 vector. The conditioned media were collected 20 hr after transient transfection with PAMP (or with empty vector), and the A $\beta$ <sub>40</sub> and A $\beta$ <sub>42</sub> levels were measured by ELISA (Zhang L, *et al.*, J Biol Chem 1999; 274: 8966-8972.). In Western blots of lysates of these cells, the use of anti-V5 (Invitrogen, CA) and enhanced chemiluminescence (Amersham) detected a V5- immunoreactive band of ~110 kDa which was reduced to ~80 kDa following Endo H digestion (equivalent to the size predicted from the PAMP amino acid sequence), confirming the predicted glycosylation of PAMP. In addition, a series of about 7-10 kDa fragments were observed, which are predicted to contain the TM domain and short C-terminus of PAMP plus the 3 kDa V5- epitope. These C-terminal derivatives may be authentic cleavage products of full-length PAMP, or, alternatively, a proteolytic artifact arising from the attachment of the V5-epitope to the C-terminus of PAMP.

Reciprocal immunoprecipitation studies in cells expressing combinations of transfected V5-tagged-PAMP, transfected wild type or mutant PS1, transfected wild type PS2, or endogenous presenilins, confirmed the PS1:PAMP interaction, and showed a similar interaction between PAMP and

PS2. In contrast, immunoprecipitation of other ER-resident proteins (e.g., calnexin) failed to show any evidence of an interaction between these proteins and PAMP. Glycerol velocity gradient analysis of the native conformation of PAMP revealed that PAMP was co-eluted into the same high molecular weight fractions as PS1 and PS2, indicating that it is an authentic component of the high molecular weight presenilin protein complexes. These biochemical data were supported by immunocytochemical studies, which showed that transfected PAMP and endogenous PS1 strongly co-localized in the ER and Golgi in MDCK canine kidney/epithelial cells (ATCC). Similar studies with PS2 confirmed that PAMP also tightly associates with both endogenous PS2 in human brain and with transfected PS2 in HEK293 cells.

**The PAMP gene.** Chromosomal locations and genetic map positions of the murine and human PAMPS were obtained from public genetic and transcriptional maps ([www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)). The gene encoding PAMP is located on human chromosome 1 near the genetic markers D1S1595 and D1S2844. The 5'- end of the PAMP gene is embedded in the 5'- end of the coatmer gene encoded on the opposite strand. The human PAMP gene is close to a cluster of markers which have yielded positive, but sub-significant evidence for linkage to or association with Alzheimer Disease in two independent genome wide surveys (Kehoe P, *et al.* Hum Mol Genet 1999; 8: 237-245). The murine PAMP maps within a 700 Kb interval of murine chromosome 1 which contains the gene defect associated with *Looptail* phenotype in mice (Underhill DA, *et al.*, Genomics 1999; 55: 185-193). Mice heterozygous for *Looptail* show developmental defects in dorsal axial structures including notochord, brain, spinal cord, and somites (Greene ND, *et al.*, Mech Dev 1998; 73: 59-72.), which are reminiscent of those observed in PS1<sup>-/-</sup> mice (Shen J, *et al.*, Cell 1997; 89: 629-639; Wong PC, *et al.*, Nature 1997; 387:288-292). These observations suggest that the presenilin: PAMP complex may be involved in both  $\beta$ APP and Notch processing.

**C. elegans homolog of PAMP.** The *C. elegans* homolog of PAMP corresponds to the *aph-2* gene. Mutations in *aph-2* have been identified in a screen for mutants with phenotypes identical to embryonic mutant phenotypes caused by loss of *glp-1* activity, i.e., lack of an anterior pharynx, e.g. cDNA clone. The EST corresponding to *aph-2*, (cDNA clone yk477b8, kindly provided by Y. Kohara, National Institute of Genetics, Japan) was sequenced and the coding region (SEQ ID NO: 11) found to match

exactly the Genefinder prediction made by the *C. elegans* sequencing consortium (Genbank; Accession No. Z75714). Double stranded RNA interference (RNAi) confirmed the mutant phenotype of *aph-2*. Sense and antisense RNA were transcribed *in vitro* from PCR product amplified from the phage yk477b8. After annealing equal quantities of sense and antisense products, the dsRNA product made was injected into L4 stage wild-type worms. The chosen line of worms, designated lin-12(n302) (Greenwald and Seydoux, Nature 1990: 346:197-199; Greenwald, *et al.*, Cell 1983: 34; 435-444) was obtained from the Caenorhabditis Genetics Center. Injected animals were transferred to fresh plates daily and the progeny scored at least 36 hours after injection for the embryonic lethal phenotype and 4-5 days after injection for the egg-laying phenotypes. Animals injected with dsRNA from yk477b8 template produced eggs that lacked an anterior pharynx. These results support the notion that *aph-2/PAMP* contributes to cell interactions mediated by *glp-1/Notch* in the embryo.

**Functional role for the PAMP:presenilin complexes in  $\beta$ APP processing.** To examine a functional role for the PAMP:presenilin complexes in  $\beta$ APP processing, the interactions between PAMP, PS1, and  $\beta$ APP, and its derivatives were investigated. The cell lines used were transiently transfected with V5-tagged PAMP, and stably expressed wild type  $\beta$ APP<sub>695</sub> in addition to one of wild type PS1, wild type PS2, PS1-L392V mutant, or PS1-D385A mutant. The PS1-L392V mutation is a pathogenic mutation associated with familial AD (Sherrington R, *et al.*, Nature 1995; 375:754-760) and with increased secretion of  $A\beta_{42}$  (Scheuner D, *et al.* Nature Med 1996; 2: 864-870, Citron M, *et al.* Nature Med 1997; 3: 67-72). The PS1-D385A mutation is a loss of function mutation associated with inhibition of PS1 endoproteolysis and a decrease in  $\gamma$ -secretase activity (Wolfe MS, *et al.*, Nature 1999; 398: 513-517). The conditioned media were collected 20 hr after transient transfection with PAMP (or with empty vector), and the  $A\beta_{40}$  and  $A\beta_{42}$  levels were measured by ELISA (Zhang L, *et al.*, J Biol Chem 1999; 274: 8966-8972). Analysis of Western blots from these co-immunoprecipitation experiments revealed that PAMP holoprotein (and C-terminally tagged proteolytic fragments of PAMP) interacted in equivalent degrees with wild type PS1, wild type PS2, PS1-L392V mutant, and PS1-D385A mutant proteins. In addition, PAMP holoprotein and the C-terminal proteolytic fragments of PAMP also co-immunoprecipitated with the C-terminal proteolytic fragments of  $\beta$ APP

but not  $\beta$ APP holoprotein in lysates of cells expressing either  $\beta$ APP holoprotein or just the C-terminal 99 amino acids of  $\beta$ APP. Significantly, compared to cells expressing equivalent quantities of wild type PS1, cell lines expressing pathogenic mutations of PS1 showed increased amounts of C-terminal  $\beta$ APP fragments co-immunoprecipitating with PAMP. Conversely, cell lines expressing the loss-of-function PS1-D385A mutation showed greatly reduced amounts of C-terminal  $\beta$ APP derivatives co-immunoprecipitating with PAMP despite the presence of very large amounts of C-terminal  $\beta$ APP derivatives in these cells.

- 10        These results were confirmed in HEK293 cells over-expressing either  $\beta$ APP<sub>Swedish</sub> or the SpC99- $\beta$ APP cDNA. The latter encodes the C-terminal 99 residues of  $\beta$ APP (corresponding to the products of  $\beta$ -secretase cleavage) plus the  $\beta$ APP signal peptide. The interaction of PAMP appears much stronger with C99- $\beta$ APP than that with C83- $\beta$ APP. However, C83- $\beta$ APP
- 15        is much less abundant in these cells (Fig. 6b, middle panel, lanes 1-4). In fact, PAMP does interact with both C99- and C83- $\beta$ APP stubs (see Fig. 6c, lane 9 and Fig. 8d). Cumulatively, these results indicate that PAMP likely interacts with the C-terminal derivatives of  $\beta$ APP which are the immediate precursors of A $\beta$  and p3. However, of greater interest, the genotype of the co-expressed
- 20        PS1 molecule dynamically influenced the interaction between PAMP and C99-/C83- $\beta$ APP stubs. Thus, more C-terminal  $\beta$ APP fragments co-immunoprecipitated with PAMP in cells expressing the FAD-associated PS1-L392V mutation compared to cells expressing wild type PS1 (and equivalent quantities of PAMP and C99- $\beta$ APP). Conversely, much less C-terminal  $\beta$ APP
- 25        derivatives co-immunoprecipitated with PAMP in cell lines expressing the loss-of-function PS1-D385A mutation (despite the presence of very large amounts of C-terminal  $\beta$ APP derivatives in these cells). These effects are more easily seen in cells over-expressing the C99- $\beta$ APP construct. However, similar but less pronounced differences were also observed in cells over-
- 30        expressing full-length  $\beta$ APP<sub>Swedish</sub>. More importantly, the PS1-sequence-related differences in the interaction of PAMP with C-terminal  $\beta$ APP derivatives were most evident within 24 hours of transient transfection of PAMP. By 72 hours, the PS1-sequence-related differences were largely abolished. This dynamic change in the interaction of PAMP with C99-/C83-
- 35         $\beta$ APP was not due to changes in the levels of PS1, C-terminal  $\beta$ APP derivatives or PAMP. One interpretation of these results is that the

presenilins may be dynamically involved in regulating or loading PAMP with the substrates of  $\gamma$ -secretase.

- Presenilin binding domains of PAMP.** In transiently transfected cells (in which the 7-10 kDa C-terminal of PAMP can be detected), anti-PS1 immunoprecipitation products contain both full length PAMP and the ~7-10 kDa C-terminal PAMP fragments. Similarly, in these cells, immunoprecipitation with antibodies to the C-terminus of  $\beta$ APP (Ab369) also gives C-terminal PAMP epitopes. The TM domain of PAMP is not highly conserved in evolution. These results suggest that the C99/C83- $\beta$ APP and PS1/PS2-binding domain(s) of PAMP are in the TM domain or C-terminus.

### Discussion

- The above results indicate that PAMP is a component of the PS1 and PS2 intracellular complexes. The observations that PAMP also binds to the C-terminal fragment of  $\beta$ APP (arising from  $\alpha$ - and  $\beta$ -secretase cleavage of full length  $\beta$ APP), that the degree of binding of these fragments to PAMP is modulated by mutations in PS1, and that the direction of this modulation is congruent with the effects of each mutant of A $\beta$  production (*i.e.*, the pathogenic L392V mutation increases binding to PAMP and increases A $\beta_{42}$  production whereas the D385A mutation has the opposite effects) strongly argues that PAMP is part of a functional complex involved in processing of C-terminal  $\beta$ APP derivatives. Similarly, the observation that inhibition of PAMP expression in *C. elegans* leads to a phenotype similar to that of *glp/Notch* loss of function, argues that PAMP, like PS1 and PS2, is also a functional component of the pathways involved in processing of *Notch*. This conclusion is strengthened by the fact that the murine PAMP gene maps within a 700 kb interval on murine chromosome 1 which carries the *Looptail* mutant, and is thus likely to be the site of the *Looptail* mutation. *Looptail* has a number of phenotypic similarities to those of *Notch* and PS1 knockouts in mice. Because *Looptail* is a model of human spinal cord malformations including spina bifida, PAMP biology may also provide some useful insights into this neurological developmental defect as well.

- At the current time the exact role of PAMP in the presenilin-complex-mediated processing of  $\beta$ APP and *Notch*-like molecules is not fully defined. Inspection of the primary amino acid sequence of PAMP does not reveal very strong homologies to known proteases. However, the

recombinant expression systems of the invention permit evaluation of three-dimensional structure of PAMP; it is possible that PAMP itself has a protease activity. However, it is currently more plausible that PAMP plays another role in  $\beta$ APP and *Notch* processing. Thus, PAMP may be involved in the function of PS1 and PS2 complexes by binding substrates for  $\gamma$ -secretase. The efficacy of this binding is clearly modulated by PS1 mutations in a direction which is commensurate with the effect of these mutations on  $\gamma$ -secretase activity. Alternatively, PAMP may have a regulatory role on the activity of the presenilin complexes. This is consistent with the observation that residues 625-641 of human and murine PAMP contain a motif similar to cyclic nucleotide binding domains of several other unrelated proteins.

Regardless of its precise role, it is clear that PAMP and PS1 both play important roles in  $\gamma$ -secretase mediated processing of  $\beta$ APP. Hence, knowledge of PAMP and its biology will now serve as a target for efforts to manipulate the function of the presenilin complexes in patients with Alzheimer Disease and related disorders, patients with malignancies (in which the presenilins have been implicated by virtue of a role in programmed cell death), and in disorders of development especially of the spinal cord and brain (in view of the known effects of PS1 knockout and the strong likelihood that PAMP is the site of *Looptail* mutations in mice). In particular, knowledge of the domains of PAMP involved in binding presenilins and  $\beta$ APP derivatives (which currently appears to be located within the C-terminal transmembrane and hydrophilic domains of PAMP) and the identification of putative ligands interacting with the conserved domains at the hydrophilic N-terminus of PAMP will considerably expedite this goal.

It has been found that the strength of the interaction between PAMP and the C-terminal fragments of  $\beta$ APP (which is the precursor A $\beta$ ) is determined by the genotype at PS1. Thus, clinical mutations in PS1 which cause Alzheimer's Disease and an increase in the production of A $\beta_{42}$  are associated with increased binding of the C-terminal fragments of  $\beta$ APP to PAMP. Conversely, loss of function mutations in PS1 (Asp385Ala) which inhibit  $\gamma$ -secretase cleavage of C-terminal fragments of  $\beta$ APP, are associated with abolition of the interaction between PAMP and the C-terminal fragments of  $\beta$ APP.

Finally, the apparent C-terminal proteolytic derivatives of PAMP could either be authentic, or simply artefacts due to the V-5 tag. If they are

authentic, this observation raises the possibility that PAMP may undergo post-translational processing events which are potentially similar to those of  $\beta$ APP and/or *Notch*. Three observations support our discovery of PAMP. First, in contrast to  $\beta$ APP and *Notch*, which are not major constituents of the high molecular weight presenilin complexes, and which can only be inconsistently shown to be directly associated with PS1/PS2, PAMP is a major stoichiometric component of the presenilin complexes. Second, PAMP selectively interacts only with C-terminal derivatives of  $\beta$ APP which are substrates for  $\gamma$ -secretase cleavage, and this interaction is modulated by PS1 mutations in a way which reflects the functional consequences of these PS1 mutations. Third, inhibition of PAMP expression in *C. elegans* leads to a disease phenotype likely to be in the *glp/Notch* signaling pathway.

**EXAMPLE 2: PAMP mutants useful for studies on Alzheimer's Disease**

Site-directed mutagenesis was used to generate the following artificial mutations in PAMP:

	Cys:	PAMP <sub>C230A</sub> in the 4 conserved cystine motif
	DYIGS:	PAMP <sub>D336A/Y337A</sub> in the central conserved region
20	D369L:	PAMP <sub><math>\Delta</math>312-369</sub> in the central conserved region
	D340X:	PAMP <sub><math>\Delta</math>312-340</sub> in the central conserved region
	YDT:	PAMP <sub>D458A</sub> in the putative 'aspartyl protease' DTA site
	SPAF:	PAMP <sub>P633A/F635A</sub> in the SPAF motif
	TM:	PAMP <sub>S683A</sub> in the TM domain
25	C3D:	PAMP <sub><math>\Delta</math>630-668</sub> in the conserved region adjacent to the TM domain

To further examine the role of PAMP in  $\beta$ APP processing, we inserted PAMP cDNAs harboring the above mutations, as well as normal/wild type PAMP (PAMP<sub>wt</sub>) cDNA and the cDNA for an unrelated protein (LacZ), in frame into pcDNA6 vectors. A series of HEK293 cell lines stably expressing endogenous PS1,  $\beta$ APP<sub>Swedish</sub> and either wild type PAMP or PAMP constructs in which various conserved domains had been mutated or deleted, were then created by transfection. PAMP expressing cells were selected with blasticidin to generate stable cell lines. Conditioned media from these cell lines were collected after 6-24 hours and A $\beta$ <sub>40</sub> and A $\beta$ <sub>42</sub> were measured by ELISA.



In the PAMP<sub>D336A/Y337A</sub> mutant, both A $\beta$ <sub>40</sub> and A $\beta$ <sub>42</sub> levels were increased, and there was also a 68% increase in A $\beta$ <sub>42</sub>/A $\beta$ <sub>40</sub> ratio which is very similar to that observed in clinical mutations in APP, PS1, and PS2, associated with early onset Alzheimer Disease. The A $\beta$ <sub>42</sub>/A $\beta$ <sub>40</sub> ratio was also increased in one cell line expressing the PAMP<sub>C230A</sub> mutant.

In contrast, both the total A $\beta$ <sub>42</sub> and A $\beta$ <sub>40</sub> levels and the A $\beta$ <sub>42</sub>/A $\beta$ <sub>40</sub> ratio were massively reduced (to only 18% of the control) in the PAMP <sub>$\Delta$ 312-369</sub> mutant. A similar but less profound reduction of both the total A $\beta$ <sub>42</sub> and A $\beta$ <sub>40</sub> levels and the A $\beta$ <sub>42</sub>/A $\beta$ <sub>40</sub> ratio was observed in the conditioned medium from the PAMP <sub>$\Delta$ 312-340</sub> cell lines.

There is no apparent difference in A $\beta$ <sub>42</sub> or A $\beta$ <sub>40</sub> levels, or in the A $\beta$ <sub>42</sub>/A $\beta$ <sub>40</sub> ratio, when the PAMP<sub>wt</sub>, PAMP<sub>D458A</sub>, PAMP <sub>$\Delta$ 330-668</sub>, PAMP<sub>P633A/F635A</sub>, and PAMP<sub>S683A</sub> cells were compared to control lines (expressing LacZ, or empty vector).

Thus, certain PAMP mutants cause biochemical changes similar to those induced by mutations in the  $\beta$ APP, PS1, and PS2 genes which give rise to Alzheimer's Disease. These artificial PAMP mutations can therefore be used to generate cellular and other model systems to design treatments and preventions for Alzheimer's Disease related disorders. These mutations also show that PAMP is involved in the pathogenesis of AD, and may provide information for the design of specific molecular diagnostics or therapeutics.

When compared to mock-transfected or LacZ transfected cells, overexpression of wild type PAMP, and overexpression of most PAMP mutation- or deletion-constructs had no significant effect on A $\beta$  secretion. However, missense mutation of the conserved DYIGS motif to AAIIGS (residues 336-340 of human PAMP) caused a significant increase in A $\beta$ <sub>42</sub> secretion, a smaller increase in A $\beta$ <sub>40</sub> secretion, and an increase in the A $\beta$ <sub>42</sub>/A $\beta$ <sub>40</sub> ratio ( $p < 0.001$ ; Table 2). This increase in A $\beta$ <sub>42</sub> production was equivalent to that of FAD-related missense mutations in PS1. Conversely, deletion of the DYIGS domain in two independent constructs (PAMP <sub>$\Delta$ 312-369</sub> and PAMP <sub>$\Delta$ 312-340</sub>) caused a significant reduction in both A $\beta$ <sub>42</sub> and A $\beta$ <sub>40</sub> secretion which was more profound in PAMP <sub>$\Delta$ 312-369</sub> cells than in PAMP <sub>$\Delta$ 312-340</sub> cells (Table 2). The magnitude of the reduction in A $\beta$  secretion in PAMP <sub>$\Delta$ 312-369</sub> cells was equivalent to that observed with the PS1-D385A loss-of-function mutation. Somewhat unexpectedly, and in contrast to PS1<sup>-/-</sup> and PS1-D385A cells, the reduction in A $\beta$  secretion in NCT <sub>$\Delta$ 312-369</sub> and NCT <sub>$\Delta$ 312-340</sub> cells was not

- accompanied by the expected accumulation of C99- and C83- $\beta$ APP stubs. Since there was no consistent change in the levels of soluble  $\beta$ APP ( $\beta$ APP<sub>s</sub>) in the conditioned medium of any of the PAMP mutant cells, the most probable explanation for this result is that C99- and C83- $\beta$ APP stubs which do not enter the PAMP:presenilin complex for  $\gamma$ -secretase cleavage to A $\beta$  may be degraded by other pathways.

- The effects of PAMP mutations on A $\beta$  secretion were not due to trivial explanations such as differences in the levels of PAMP,  $\beta$ APP holoprotein, or PS1/PS2. None of these mutations caused any consistent, detectable change in the amount of APP<sub>s</sub> in conditioned medium or in the amount of C99/C83- $\beta$ APP that could be co-immunoprecipitated with PAMP. However, both the PAMP <sub>$\Delta$ 312-369</sub> mutant and the PAMP <sub>$\Delta$ 312-340</sub> deletion mutant significantly reduced the amount of PS1 which could be co-immunoprecipitated with PAMP. Interestingly, the reduction in efficiency of binding to PS1 was proportional to the reduction in A $\beta$  secretion induced by each deletion mutant. Multiple mechanisms underlying the effect of mutations in the first conserved domain can explain these results. This domain contains no obvious functional motifs (e.g., for glycosylation etc.), nor does it have significant sequence homology to other known proteins. Consequently, the three functionally active PAMP mutations either affect a presenilin-binding domain in PAMP, or affect a specific regulatory domain of PAMP which modulates both direct binding of PAMP to PS1 and the subsequent  $\gamma$ -secretase-mediated cleavage of PAMP-bound C99- and C83- $\beta$ APP stubs.

Table 2

Transfection	Normalized $AB_{42}$	Normalized $AB_{40}$	$AB_{42}/AB_{40}$ Ratio
Mock (LacZ/empty vector)	1.0	1.0	1.0
Wild type nicastrin	$1.03 \pm 0.09$	$1.05 \pm 0.07$	$0.99 \pm 0.07$
D336A/Y337A	$3.09 \pm 0.59$ ( $p < 0.001$ )	$1.61 \pm 0.19$ ( $p = 0.001$ )	$1.81 \pm 0.15$ ( $p < 0.001$ )
Nicastrin $_{\Delta 312-369}$	$0.05 \pm 0.04$ ( $p < 0.001$ )	$0.31 \pm 0.06$ ( $p < 0.001$ )	$0.09 \pm 0.05$ ( $p < 0.001$ )
Nicastrin $_{\Delta 312-340}$	$0.33 \pm 0.04$ ( $p = 0.002$ )	$0.55 \pm 0.04$ ( $p = 0.001$ )	$0.59 \pm 0.06$ ( $p = 0.003$ )

- The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and the accompanying figures. Such modifications are intended to fall within the scope of the appended claims.

- It is further to be understood that values are approximate, and are provided for description.

Patents, patent applications, and publications are cited throughout this application, the disclosures of which are incorporated herein by reference in their entireties.

WE CLAIM:

1. An isolated presenilin associated membrane protein (PAMP), or a functional fragment thereof.  
5
2. The PAMP of claim 1, which is human PAMP (SEQ ID NO: 14).
3. The PAMP of claim 1, which is mouse PAMP (SEQ ID NO: 16), *D. Melanogaster* (SEQ ID NO: 18) or *C. elegans* PAMP (SEQ ID NO: 12).  
10
4. The PAMP of claim 1, which is a mutant PAMP.
5. The mutant PAMP of claim 4 wherein the mutation results in biochemical changes similar to those induced by mutations in presenilin-1, presenilin-2, or  $\beta$ -amyloid precursor protein associated with familial  
15 Alzheimer's Disease.
6. The mutant PAMP of claim 5, wherein the mutation is to an amino acid residue selected from the group consisting of D336, Y337, C230, and both D336 and Y337.  
20
7. An isolated nucleic acid encoding the PAMP of claim 1.
8. The nucleic acid of claim 7, which is human (SEQ ID NO: 13).  
25
9. The nucleic acid of claim 7, which is mouse (SEQ ID NO: 15), *D. Melanogaster* (SEQ ID NO: 17) or *C. elegans* (SEQ ID NO: 11).
10. A vector comprising the nucleic acid of claim 7 operatively  
30 associated with an expression control sequence.
11. A cell transfected with the vector of claim 10.
12. A method for producing PAMP, which method comprises  
35 culturing the cell of claim 11 under conditions that permit expression of PAMP.

13. An isolated nucleic acid encoding the mutant PAMP of claim 4.
14. The nucleic acid of claim 13, wherein the mutation results in a change to an amino acid residue selected from the group consisting of D336, Y337, C230, and both D336 and Y337.
15. A vector comprising the nucleic acid of claim 13 operatively associated with an expression control sequence.
16. A cell transfected with the vector of claim 15.
17. A method for producing mutant PAMP, which method comprises culturing the cell of claim 16 under conditions that permit expression of the mutant PAMP.
18. A transgenic animal, comprising a transgene encoding presenilin associated membrane protein (PAMP) which is expressed in neural cells such that the animal detectably expresses *PAMP* mRNA.
19. The transgenic animal of claim 18, which detectably expresses PAMP protein.
20. The transgenic animal of claim 19, which processes  $\beta$ -amyloid precursor protein to produce amyloid- $\beta$  peptide.
21. The transgenic animal of claim 18, which is a mouse.
22. The transgenic animal of claim 18, wherein PAMP is human PAMP (SEQ ID NO: 14).
23. The transgenic animal of claim 18, wherein said PAMP is a mutant PAMP.
24. The transgenic animal of claim 18, further comprising a second transgene encoding a human presenilin-1, human presenilin-2 or human  $\beta$ -amyloid precursor protein, wherein the human presenilin-1, human presenilin-

- 2, or human  $\beta$ -amyloid precursor protein is expressed at a level that permits its detection.
25. An animal containing a nucleic acid that expresses an  
5 endogenous presenilin associated membrane protein (PAMP) at a higher or lower level relative to expression level in a wild-type animal.
26. The animal of claim 25, prepared by homologous recombination-mediated targeting of an endogenous PAMP gene.  
10
27. The animal of claim 25, prepared by translocation of P-elements.
28. The animal of claim 25, prepared by chemical mutagenesis.  
15
29. An isolated cell containing a nucleic acid that expresses a mutant presenilin associated membrane protein (PAMP).
30. The cell of claim 25, wherein the mutation results in biochemical  
20 changes similar to those induced by mutations in presenilin-1, presenilin-2 or  $\beta$ -amyloid precursor protein associated with familial Alzheimer's Disease.
31. A reconstituted system for measuring presenilin associated  
25 membrane protein (PAMP) activity, comprising PAMP or a functional fragment thereof, and a PAMP substrate.
32. The reconstituted system of claim 31, which is a whole cell.
33. The reconstituted system of claim 31, wherein said whole cell  
30 contains a first nucleic acid that expresses said PAMP and a second nucleic acid that expresses said substrate.
34. The reconstituted system of claim 31, wherein said substrate is  
35 selected from the group consisting of presenilin-1 protein, presenilin-2 protein and  $\beta$ -amyloid precursor protein.

35. A complex between a presenilin associated membrane protein (PAMP) and an agent which provides a detectable conformational change in said PAMP upon interaction with a substance being analyzed for activity against a neurodegenerative disease.
- 5 36. The complex of claim 35, further comprising presenilin 1 protein, presenilin 2 protein,  $\beta$ -amyloid precursor protein, or a combination thereof.
- 10 37. A method for detecting a mutation in presenilin associated membrane protein (PAMP) associated with disease or a related neurological disorder, which method comprises detecting a variation in a sequence of a gene encoding PAMP obtained from an individual diagnosed with or suspected of having a neurodegenerative disorder.
- 15 38. A method for diagnosing individuals predisposed to or having a neurodegenerative disorder, which method comprises detecting a mutation in a gene encoding PAMP obtained from an individual.
- 20 39. The method according to claim 38, wherein detection of the mutation comprises measuring a level of transcriptional activity of the gene.
40. The method according to claim 38, wherein detection of the mutation comprises measuring PAMP activity.
- 25 41. The method of claim 40, wherein said PAMP activity comprises PAMP expression level or activity of a product of a PAMP modified substrate.
- 30 42. A method for identifying a compound that modulates PAMP activity, which method comprises detecting modulation of PAMP expression in a transgenic animal that expresses PAMP, wherein the animal is contacted with the compound.
43. A method for identifying a compound that modulates PAMP activity, which method comprises detecting a change in PAMP activity in the reconstituted system of claim 31 contacted with a test compound.
- 35

44. A method for identifying a compound that modulates PAMP activity, which method comprises detecting a conformational or functional change in PAMP in the complex of claim 35 contacted with a test compound.
- 5 45. The method of claim 44, wherein the compound is a protein that interacts with PAMP.



NSDUCID <WFO 0060069A:1 >

Hum: 360 DSFVLEQVALRTSL+LMMHTDPY+SQKNSV+NOVEDLLATLEKSGACIVANTLRRPQK 419  
 Mou DSFVLEQVALRTSL+LMMHTDP+SQKNSV+NOVEDLLATLEKSGACIV+LRR QS  
 Dros D ++G + ++++L + ++ Q+ + L KS G I + S  
 C.eleg D +E+ Q+ + + ++H D ++ + Q + ++ +E+ G A L +P+ S

Hum: 420 QPLPSSIQREFLRANISGVVLADHSGAFHNKYYQIYDTAENINVSYPWISPEEDINF 479  
 Mou Q PESSIQREFLRANISGVVLADHSG+FIN+YQSIYDTAENIN+YPEW S EEDINF  
 Dros LPP+S Q FLR N + ++L + NKYY S YD A+N++ +Y L  
 C.eleg +PP+S F +A ++ Y+LA + + + S+ D EW E +

Hum: 480 VDTAKALAN+YVGLMAL+YELAGTNFSDTVQADPQTVTRLLYGLKANN+FOFILR 539  
 Mous VDTAKALAN+YVGL MAL+YELAGTNF+ ++QADPQTVTRLLYGL+ANN+FOFIL+  
 Dros V D DV++++ ALX+ G ++ T A+P LY FL A+ F++  
 C.eleg + + V+T + A + G + D + +T ++ LI +N WF

Hum: 540 QDLRSYLDGRLQHYVANSFPNTYVQYALANLGTGVNLTRECCDPSKVP+KDL 599  
 Mous DLRSYL D FLQHYVANSFPNTYVQYAL NLGTG NLTRECCDPSKVP+KDL  
 Dros S L + P YI+V + + Y L L+ ++ R+ C D  
 C.eleg Q L SY G YI++ SFT ++ +AL + T+ + + C + +

Hum: 600 YEYXWQGPLHSHNETDRLPCRVSTABLRALSPALSCMSSTESTYNTSKKQIAR 659  
 Mous YEYXWQGP +SN T+RLP+CVRST BLARALSPALSCMSSTESTYNTSKKQIAR  
 Dros FLH + + C +? + ALSPAF + WSS YSTWTS W AR  
 C.eleg Y Y+W P N + C++S +SPA + + +T YSTM ES +

Hum: 660 IFLIASKELITITVGFILFSLIVTCINAKADVLFIAPREFCAVSY 709  
 Mous IFLIASKELE ITL VGF L+PSLIVTCINAKADVL+APREFCAVSY  
 Dros IFL S ++ TL+VG +LI S + Y I+ +++VLF  
 C.eleg ++L+ E + + +I+L+ + + ++ FI EP A

Figure 1B

1/19

## SEQUENCE LISTING

&lt;110&gt; The Governing Council of The University of Toronto

<120> A novel presenilin associated membrane  
protein and uses thereof

&lt;130&gt; 9267-61/FAR

&lt;160&gt; 19

&lt;170&gt; FastSEQ for Windows Version 3.0

&lt;210&gt; 1

&lt;400&gt; 1

000

&lt;210&gt; 2

&lt;400&gt; 2

000

&lt;210&gt; 3

&lt;211&gt; 422

&lt;212&gt; DNA

&lt;213&gt; mouse

&lt;400&gt; 3

```
cccagcggag aggcaagatg gctacgacta ggggcggtc tgggcctgac ccaggaagtc
60 ggggtcttct tcttctgtct ttttcgtg tactggcagg attgtgtggg ggaaactcag
120 tggagaggaa aatctacatt cccttaaata aaacagctcc ttgtgtccgc ctgctcaacg
180 ccactcatca gattggctgc cagtcttcaa ttagtgggga tacagggggt atccatgtag
240 tggagaaaaga agaagactga agtgggtgtt gacgatggcc ccaaccccct tacatggtct
300 gctggaggga agtcttcaca gagatgtaat ggagaagctg aggacaacag tagatcctgg
360 tcttgccgtg attagcagcc actcacttaa gtttctctag tgtgagtgcc aatgatgggt
420 tt
422
```

&lt;210&gt; 4

&lt;211&gt; 473

&lt;212&gt; DNA

&lt;213&gt; unknown

&lt;220&gt;

&lt;223&gt; EST from unknown organism

&lt;400&gt; 4

2/19

tgagagaggaa aatctacatt cccctaaata aaacagctcc ttgtgtccgc ctgctcaacg  
60  
ccactcatca gattggctgc cagctcttcaa ttagtgggga tacagggggtt atccatgtag  
120  
tgagagaaaga agaagacctg aagtgggtgt tgaccgatgg ccccaacccc ccttacatgg  
180  
ttctgctgga gggcaagctc ttcaccagag atgtaatgga gaagctgaag ggaacaagca  
240  
gtagaatcgc tggctcttgc gtgactctag ccaagcccaa ctcaacttca agcttctctc  
300  
ctagtgtgca gtgcccaaat gatgggttg gtaattactc caactcctac gggccagagt  
360  
ttgtcactg gaagaaaaca ctgtggaatg aactcggcaa aggcttggct tatgaagacc  
420  
ttagtttccc caatcttctt cctgggatg aggaccgaaa caaggtcacc aag  
473

&lt;210&gt; 5

&lt;220&gt;

&lt;223&gt; null

&lt;400&gt; 5

000

&lt;210&gt; 6

&lt;211&gt; 463

&lt;212&gt; DNA

&lt;213&gt; unknown

&lt;220&gt;

&lt;223&gt; EST from unknown organism

&lt;400&gt; 6

gggctcgaaa catctctggc gtggtctctg ctgaccactc tggctccttc cacaatcggt  
60  
attaccagag catttatgac acggctgaga acattaatgt gacctatcct gagtggcaga  
120  
gccatgaaga ggaacctaac tttgtgacag acaactgccaa ggcactggcg aatgtggcca  
180  
cagtgtctgc gcgtgcactg tatgagcttg caggaggaac caacttcagc agctccatcc  
240  
aggctgatcc ccagacagtt acaactctgc tctatgggtt cctggttaga gctaacaaat  
300  
catggtttca gtgatcctg aaacatgacc taaggctcta ttggatgac aggcctcttc  
360  
aacactacat cgccgtctcc agccctacca acacgactta cgttgtgcag tacgccttgg  
420  
caaacctgac tgggcaaggc gaccaacctc acccgagagc agt  
463

&lt;210&gt; 7

&lt;211&gt; 481

&lt;212&gt; DNA

&lt;213&gt; unknown

&lt;220&gt;

&lt;223&gt; EST from unknown organism

<210> 8  
<211> 398  
<212> DNA  
<213> unknown

<400> B

<210> 9  
<211> 172  
<212> DNA  
<213> unknown

<400> 9

INSIDOCID <WQ 00000000 1 1 >

4/19

attcctaatt gccagcaaa agcttgagtt caccacgctg atcgtgggct tc  
172

<210> 10  
<211> 425  
<212> DNA  
<213> unknown

<220>  
<223> EST from unknown organism

<400> 10  
tttttttttt ttttttgat tgcataattt taatgaaact tgctatttat atacttacaa  
60  
aaaaaaaaaa aaaggaaaaa accccaacaa aaatagataa ttatagtta ataataaaaa  
120  
gtacaactga gcactgtggg ctggagggtg gatacccaact taacagcgtg cccacactaa  
180  
catgccatct gcacacctgg agaaaggaca gtgggaaaga gacactggct cagccaggga  
240  
atccatttct tccctaaggg ttcagggtag ttgaatgcag atgcacaatc ttccacaccc  
300  
tcttctcggt gcagcagggt gctgaatatg ggggaggggt gtcgggtgac agtgaggta  
360  
gagggcagta cagggcagga tggaaaggaca gaaggatatcc cgagaaaggg cagaggaggg  
420  
tgggt  
425

<210> 11  
<211> 4560  
<212> DNA  
<213> C. Elegans

<400> 11  
attaagaacg aatgagtcga tagaagcact gaaaaatgaa gaaatggcta gttatagtat  
60  
taattatcgc tggaatacga tgcgacggat ttctcgatca agttttccga actctgttca  
120  
ttggagaagg aaatgcgtgc tatagaactt ttaataaaac gcacgaatc ggttgtcaag  
180  
gtaaaaattg aatgatttca aataattaca tataaaaaaa tattgcactg ttttttcatt  
240  
attttcattg aaaattagtg tcaaaatag tataaatcaa tatttatctg aaaataactg  
300  
gaaatataga gaaagtgtc caaaatggcc aaacgttgt caattgccga agacgatact  
360  
ctataataaa cggcaattgg caactttcgg gctgttttcc aacactgttc aatttgtcag  
420  
atgaaaaata ttttatttcc agttaactca agtgatttcc tatattgtgg cagtgaaaaa  
480  
aattcatagg ccattttgta gaattgccga aaataactcc acctctgaat tacatgcatt  
540  
ttcactagaa aatatcattt acatacattt taatttataa atatccagta tttatttatt  
600  
ttcttaaaact cattttcaag aaaaatattt tcagctaact gagaaaaaga gaattggccta  
660

5/19

attgttcgaa tcgacaaaca ggaagacttc aaaaatctcg attcttgctg gaattcattt  
720  
tatcccaaat attccgggaa atattgggca ctctctccag tcaatttgat tctgtctgat  
780  
acaatttctc aattgaaatc atcgaaatgt ctttctggaa tagtattata taatagtggg  
840  
gaatctatct atccaggaga tgaatcaaca gcagcttcac atgatgcaga atgtccaagt  
900  
gctgcaagtg attattatct tcaagataaa aatgaagaat attgtgaaag aaagattaat  
960  
tctcgggggtg ctataacacg agatggatta atgaaaattg attgcccgat acaaatggta  
1020  
tttattgata attcaactga ttgggaatc attgagaaat gttattcaat gttcaataaa  
1080  
ccaaaagaag atggttcacg tggatatcca tattgtggaa tgagctttcg tttggctaatt  
1140  
atggcggctg gaaattcaga aatttgctat cggcgtggaa aaaacgatgc aaagctgttt  
1200  
cagatgaata ttgatagcgg gtaggttttt aaattttaag cagttaaaag aggtgaattt  
1260  
ttgcattatt aaatgcagaa tagaccgtaa atattgcatg atgagatgta tttcatgata  
1320  
tattctctta agaaaaataaa ttgaaaatt tcataggaaa ataaacaaaa ttttgcataa  
1380  
cttcagatgt tggcatttct tatctcgttt ttgttaatt taggggattt tttagtcaat  
1440  
aattgcaccg attccatgta tctctttttt tcgaatgata ttgtacctat atgccagacg  
1500  
agctataatt tcctaatttt aaaaaataaa ttgtccaaact caatgcctca atagttgaa  
1560  
ttttccagag atgctcctca actctgtggt gcaatgcaca gtgacaatat atttgcat  
1620  
ccaaactcaa ttccaaattc tccaacaaat gagacaataa tcacgagcaa atatatgatg  
1680  
gtaactgctc gaatggacag ttttggaatg attccagaga tttctgttg cgaagtatcc  
1740  
gtactaactt caattatttc tgtactcgca gcagctcgat caatgggaac acagatcgaa  
1800  
aaatggcaga aagcatcgaa tacttcgaat cgtaatgttt tcttgcattt tttcaatggt  
1860  
gaatcgttgg attatatggg aagtgggtcg gctgcgtatc agatggagta agttggaaaa  
1920  
tttaatttaa aaaacgttct agaactagta actgatcaaa aaaatttccc tattaacata  
1980  
aaatggccca aaaattccta aaaatttcaa aatttcaaaa aaaaaaatag ttcgggcgaa  
2040  
aaacataatt ctactgtgaa cctcaaattt ggcaagcttt tcaggctcgt aacatatttt  
2100  
tggaagtctg caatcaaaaa ataattcagt tttattcatt tatgataatt aattaaaaat  
2160  
ttccaacatt gtttgaatat ttttataatg atatttggtc attttaccat aattggaatg  
2220  
gttttcaatt attttccac tcttctttaa gagaaaaaat atatttgcct tcagaaatgg  
2280  
aaagtccca caaatgattc gctctgatcg aacacacatt catccaattc gcccgagtga  
2340  
gttagattat atactggaag tacaacaaat tggagttgct aaaggacgaa aatattatgt  
2400

acacgttgat ggagaacgat atcaacagaa taagacacag acagatcgag ttattgatcg  
2460  
aattgaacga ggtcttcgta gtcatgcttt tgatcttgaa aaaccatctg gaagtggaga  
2520  
taggtgggtg catcgaaaat agtttttttt ttcaagaaca tacagaaaaa gaaaagcttt  
2580  
taaacgattt tctttaaaaa ttaaaacaat ttgagcatat gtaaaactaca attccgagtg  
2640  
tcgttttttcg aaaaaagtct aaaattaaaa aaaagcttat cgctcactat ttttcgaaaa  
2700  
taagggtattt ttcttttaat aaaggcaaac gaaaaatctt cagccatgga taggtgaatt  
2760  
atagaaataa ttttcaaaaa ttttctttt tcagagttcc acccgcaagt tggcactcgt  
2820  
ttgccaagcg tgatgctcac gttcaatcag ttctccttgc accataggtt aaagaatatg  
2880  
aatatcaacg agttaattca attttgata aaaatgagtg gacagaagac gaacgagaga  
2940  
aagcaattca agagattgaa gctgtttcta ctgctattct ggcagcagcc gctgattatg  
3000  
ttggagttga aactgatgaa gttgttgcaa aagttgataa aaaattggta tgtattcttt  
3060  
tttttttaa ttttaaaact ttcagcgaca atttagatgt tttattgttg aatttgaatt  
3120  
ttgcagtatt tttaaatact taaaacaaaa tccctgatga cgcagcgatt catcgctgta  
3180  
ttttctaatt gctgaaattg aattccatat atatggaata tttcatatct ttacatataa  
3240  
acgttttttt ttttcagata accactatat tcgattgtct catcacttcc aatttctggt  
3300  
tcgactgtga ttttatgcaa aaactogatg goggtcgcta ccacaagctg ttaattctct  
3360  
acggttttaa tcaaaaaatca acatatattt caatggaatc ccatactgca ttcctaccg  
3420  
tactccattg gtttaactatt ttgcgtttgg gtagtgacaa agaaccattg aatgtgaaaa  
3480  
gtgaaaaagag ctgctcacat ctgtgtcaat ttcaagcggt gagtttttat tttaaacgaa  
3540  
tatcaataa ttaaaatagt tttccgccag ttccagatgt ataactacac gtggcaaccg  
3600  
aatcgtaca ccggaaattt cagttgtctg aaactcgcaa ttgtaaaaa agtaatgggt  
3660  
tcgccggctg tagattctca aacaccggaa gaagaaatga acacgagata ttcaaatggt  
3720  
atcggaatcg tttatattat tgaatctgtg aatttatatt tgatggaaga tgcttcattt  
3780  
gaatatacaa tgattctgat tgcggttatt ctgctttat tatcaatctt tgcagttggt  
3840  
tagttttttt tcaaaaaaaa aaattacaaa aataaatcac aagctttcga gctttctcgt  
3900  
attcgaaaaa gaaggagttt cgcattaaag aaaactagat ttgaatcag tttttctaat  
3960  
ctttagagaa attatactca catttgatgc ccagaaaagt ttgcgacttt tgagccaaaa  
4020  
gcacggtgcc aggtctcgac acgaaaaatt tatattaatt gaaaatatgt ttgcgcttt  
4080  
aaatggtact gtattttcga attctcattg ctggcgattt aaaaaaatgc attttttaaa  
4140



tcacataaaa ttgagaaaaa tcgatgaaaa atgtgcacaga aatgagtgca agaaaattaca  
4200  
gtattcttta aagggcgaca ccttttcgca ttccacaaaa ttccatcgtg tcgataccgg  
4260  
gtaccgtatt ttggaggcaa aaatcgcmaa atctcgcgtc tggataatat cgtttatcgt  
4320  
ttatgaagg aagtttttta aaataagaaa aattgcacgc tcgcgagaaat tatgcataat  
4380  
ttataaaaa ataaaaattt ttttttcag gtcgctgttc tgaacaacaa tttatcgttg  
4440  
accagggaga acccagcagcg gaaggaggag aacctcttta acaaatattt ctcttcaaca  
4500  
atgtatcata aattgattaa ttttttaat atttatattc gaaaaaatgt tcccattttt  
4560

```
<210> 12
<211> 721
<212> PRT
<213> C. Elegans
```

NSD001: 4W0 002009A1112

8/19

Phe Gly Met Ile Pro Glu Ile Ser Val Gly Glu Val Ser Val Leu Thr  
 290 295 300  
 Ser Ile Ile Ser Val Leu Ala Ala Ala Arg Ser Met Gly Thr Gln Ile  
 305 310 315  
 Glu Lys Trp Gln Lys Ala Ser Asn Thr Ser Asn Arg Asn Val Phe Phe  
 325 330 335  
 Ala Phe Phe Asn Gly Glu Ser Leu Asp Tyr Ile Gly Ser Gly Ala Ala  
 340 345 350  
 Ala Tyr Gln Met Glu Asn Gly Lys Phe Pro Gln Met Ile Arg Ser Asp  
 355 360 365  
 Arg Thr His Ile His Pro Ile Arg Pro Asn Glu Leu Asp Tyr Ile Leu  
 370 375 380  
 Glu Val Gln Gln Ile Gly Val Ala Lys Gly Arg Lys Tyr Tyr Val His  
 385 390 395  
 Val Asp Gly Glu Arg Tyr Gln Gln Asn Lys Thr Gln Thr Asp Arg Val  
 405 410 415  
 Ile Asp Arg Ile Glu Arg Gly Leu Arg Ser His Ala Phe Asp Leu Glu  
 420 425 430  
 Lys Pro Ser Gly Ser Gly Asp Arg Val Pro Pro Ala Ser Trp His Ser  
 435 440 445  
 Phe Ala Lys Ala Asp Ala His Val Gln Ser Val Leu Leu Ala Pro Tyr  
 450 455 460  
 Gly Lys Glu Tyr Glu Tyr Gln Arg Val Asn Ser Ile Leu Asp Lys Asn  
 465 470 475  
 Glu Trp Thr Glu Asp Glu Arg Glu Lys Ala Ile Gln Glu Ile Glu Ala  
 485 490 495  
 Val Ser Thr Ala Ile Leu Ala Ala Ala Asp Tyr Val Gly Val Glu  
 500 505 510  
 Thr Asp Glu Val Val Ala Lys Val Asp Lys Lys Leu Ile Thr Thr Ile  
 515 520 525  
 Phe Asp Cys Leu Ile Thr Ser Asn Phe Trp Phe Asp Cys Asp Phe Met  
 530 535 540  
 Gln Lys Leu Asp Gly Gly Arg Tyr His Lys Leu Phe Asn Ser Tyr Gly  
 545 550 555  
 Phe Asn Gln Lys Ser Thr Tyr Ile Ser Met Glu Ser His Thr Ala Phe  
 565 570 575  
 Pro Thr Val Leu His Trp Leu Thr Ile Phe Ala Leu Gly Ser Asp Lys  
 580 585 590  
 Glu Thr Leu Asn Val Lys Ser Glu Lys Ser Cys Ser His Leu Gly Gln  
 595 600 605  
 Phe Gln Ala Met Tyr Thr Tyr Thr Trp Gln Pro Asn Pro Tyr Thr Gly  
 610 615 620  
 Asn Phe Ser Cys Leu Lys Ser Ala Ile Val Lys Lys Val Met Val Ser  
 625 630 635  
 Pro Ala Val Asp Ser Gln Thr Pro Glu Glu Glu Met Asn Thr Arg Tyr  
 645 650 655  
 Ser Thr Trp Met Glu Ser Val Tyr Ile Ile Glu Ser Val Asn Leu Tyr  
 660 665 670  
 Leu Met Glu Asp Ala Ser Phe Glu Tyr Thr Met Ile Leu Ile Ala Val  
 675 680 685  
 Ile Ser Ala Leu Leu Ser Ile Phe Ala Val Gly Arg Cys Ser Glu Thr  
 690 695 700  
 Thr Phe Ile Val Asp Glu Gly Glu Pro Ala Ala Glu Gly Gly Glu Pro  
 705 710 715 720  
 Leu

9/19

<210> 13  
<211> 2949  
<212> DNA  
<213> human

<400> 13  
tctgcagaat tcggtcttgcg cctggaaaca cgaacttccg gtctcttagg ctccgggcca  
60 cagagacggg gtcagtggta gcctagagag gccctaaca gacaggagcc gaacgggggc  
120 ttccgctcag cagagaggca agatggctac ggcagggggt ggctctgggg ctgacccggg  
180 aagtcgggggt ctccttcgcc ttctgtcttt ctgcgtccta ctacagggtt tgtgcagggg  
240 aaactcagtg gagaggaaga tatatatccc cttaataaaa acagctccct gtgttcgcct  
300 gctcaacgcc actcatcaga ttgggtgcc a gtcttcaatt agtgagaca cagggggttat  
360 ccacgtagta gagaagagg aggacctaca ttgggtattg actgatggcc ccaaccccc  
420 ttacatgggt ctgctggaga gcaagcattt taccagggtt ttaatggaga agctgaaagg  
480 gagaaccagc cgaattgctg gtcttgtagt gtcccttgacc aagccagtc ctgcctcagg  
540 cttctctcct agtgtacagt gcccaaatga tgggtttggg gtttactcca attcctatgg  
600 gccagagttt gctcactgca gagaataca ttggaattcg ctgggcaatg gtttggttta  
660 tgaagacttt agtttcccca tctttcttct tgaagatgaa aatgaaacca aagtcataca  
720 gcagtctat caagatcaca acctgagtc aatgggtcga gcaaccaact tcccatatg  
780 tgccatgcag ctcttttcc acatgcctgc tgcctcagc actgccacct gcctgcggcg  
840 cagctccatc caaagcaect tcagcatcaa ccagaaatc gtctgtgacc ccctgtctga  
900 ttacaatgtg tggagcatgc taaagcctat aaatacaact gggacattaa agcctgacga  
960 cagggttggt gttgctgcc cccggctgga tagtcgttcc ttttctgga atgtggcccc  
1020 aggggctgaa agcgcagtg cttcctttgt caccagctg gctgctgctg aagctttgca  
1080 aaaggcaect gatgtgacca cctgcctccg caatgtcatg ttgtcttct tcaaggggga  
1140 aacttttgac tacattggca gctcgaggat ggtctacgat atggagaagg gcaagttcc  
1200 cgtgcagtta gagaatgtt actcattgt ggagctggga caggtggcct taagaacttc  
1260 attagagctt tggatgcaca cagatcctgt ttctcagaaa aatgagtcgt tacggaacca  
1320 ggtggaggat ctccctggca cattggagaa gagtggtgct ggtgtccctg ctgtcatcct  
1380 caggaggcca aatcagtcgc agcctctccc accatcttcc ctgcagcgat ttcttcagac  
1440 tcgaaacatc tctggcgttg ttctggctga ccactctggt gccttcata acaaatagta  
1500 ccagagtatt tacgacactg ctgagaacat taatgtgagc tatcccgaaat ggctgagccc  
1560

10/19

tgaaggaggac ctgaactttg taacagacac tgccaaggcc ctggcagatg tggccacggt  
 1620  
 gctgggagct gctctgtatg agcttgccagg aggaaccaac ttccgcgaca cagttcaggc  
 1680  
 tgatccccaa acggttaccc gcctgctcta tgggttccctg attaaagcca acaactcatg  
 1740  
 gtccagctct atcctcaggc aggacctaa gtcctacttg ggtgacgggc ctcttcacaa  
 1800  
 ttacatcgct gtctccagcc ccaccaacac cacttatggt gtacagtatg ccttggcaaa  
 1860  
 ttgactggc acagtggta acctaccgc agagcagtg caggatocaa gtaaagtccc  
 1920  
 aagtgaanaac aaggatctgt atgagtaact atgggtccag ggcctttgc attctaatag  
 1980  
 gacggaccga ctccccgggt gtgtgcgttc tactgcaaga tttagccagg ccttgtctcc  
 2040  
 tgcctttgaa ctgagtcagt ggagctctac tgaatactct acatggactg agagccgctg  
 2100  
 gaaagataat cgtgcccgga tatttctcat cgccagcaaa gagcttgagt tgatcaccc  
 2160  
 gacagtgggc ttccgcatcc tcattctctc cctcatcgte acctactgca tcaatgccaa  
 2220  
 agctgatgct cttttcattg ctccccggga gccaggagct gtgtcatact gagsaggacc  
 2280  
 scagcttttc ttgccagctc agcagttcac ttccatagagc atctgtccca ctgggacaca  
 2340  
 accactaatt tgtaactgga acctccctgg gcctgtctca gattgggatt aacataaaa  
 2400  
 agtggaaacta tccaaaagag acagggagaa ataaaataat tgccctccct cctccgctcc  
 2460  
 ccttcccctat caccctctcc ccatttccct ttccttccct actcatgcca gattttggga  
 2520  
 ttacaaatag aagcttcttg ctctctgtta actccctagt taaccaccct aatttgcct  
 2580  
 tcaggaccct tctacttttt ccttccctgc ctgtacctct ctctgctcct caccgccacc  
 2640  
 cctgtaccga gccaccttcc tgactgggaa ggacataaaa ggtttaagt cagggtcaaa  
 2700  
 ctacattgag cccctgagga caggggcctc tctgggctga gcctactgct tcttccacc  
 2760  
 tgcctttct ccaggccctc agatggcaca ttagggtggg cgtgctgcgg gtgggtatcc  
 2820  
 caccctcagc ccacagtgc cagtgttact ttttattaag ctgtaataat tatttttgtt  
 2880  
 ttgtctttt tcttttattc tttttgtaaa tatatatata atgagtttca ttaaaataga  
 2940  
 ttatccacc  
 2949

<210> 14  
 <211> 709  
 <212> PRT  
 <213> human

<400> 14

Met Ala Thr Ala Gly Gly Gly Ser Gly Ala Asp Pro Gly Ser Arg Gly

1

5

10

15

11/19

Leu Leu Arg Leu Leu Ser Phe Cys Val Leu Leu Ala Gly Leu Cys Arg  
 20 25 30  
 Gly Asn Ser Val Glu Arg Lys Ile Tyr Ile Pro Leu Asn Lys Thr Ala  
 35 40 45  
 Pro Cys Val Arg Leu Leu Asn Ala Thr His Gln Ile Gly Cys Gln Ser  
 50 55 60  
 Ser Ile Ser Gly Asp Thr Gly Val Ile His Val Val Glu Lys Glu Glu  
 65 70 75 80  
 Asp Leu Gln Trp Val Leu Thr Asp Gly Pro Asn Pro Pro Tyr Met Val  
 85 90 95  
 Leu Leu Glu Ser Lys His Phe Thr Arg Asp Leu Met Glu Lys Leu Lys  
 100 105 110  
 Gly Arg Thr Ser Arg Ile Ala Gly Leu Ala Val Ser Leu Thr Lys Pro  
 115 120 125  
 Ser Pro Ala Ser Gly Phe Ser Pro Ser Val Gln Cys Pro Asn Asp Gly  
 130 135 140  
 Phe Gly Val Tyr Ser Asn Ser Tyr Gly Pro Glu Phe Ala His Cys Arg  
 145 150 155 160  
 Glu Ile Gln Trp Asn Ser Leu Gly Asn Gly Leu Ala Tyr Glu Asp Phe  
 165 170 175  
 Ser Phe Pro Ile Phe Leu Leu Glu Asp Glu Asn Glu Thr Lys Val Ile  
 180 185 190  
 Lys Gln Cys Tyr Gln Asp His Asn Leu Ser Gln Asn Gly Ser Ala Pro  
 195 200 205  
 Thr Phe Pro Leu Cys Ala Met Gln Leu Phe Ser His Met His Ala Val  
 210 215 220  
 Ile Ser Thr Ala Thr Cys Met Arg Arg Ser Ser Ile Gln Ser Thr Phe  
 225 230 235 240  
 Ser Ile Asn Pro Glu Ile Val Cys Asp Pro Leu Ser Asp Tyr Asn Val  
 245 250 255  
 Trp Ser Met Leu Lys Pro Ile Asn Thr Thr Gly Thr Leu Lys Pro Asp  
 260 265 270  
 Asp Arg Val Val Val Ala Ala Thr Arg Leu Asp Ser Arg Ser Phe Phe  
 275 280 285  
 Trp Asn Val Ala Pro Gly Ala Glu Ser Ala Val Ala Ser Phe Val Thr  
 290 295 300  
 Gln Leu Ala Ala Ala Glu Ala Leu Gln Lys Ala Pro Asp Val Thr Thr  
 305 310 315 320  
 Leu Pro Arg Asn Val Met Phe Val Phe Phe Gln Gly Glu Thr Phe Asp  
 325 330 335  
 Tyr Ile Gly Ser Ser Arg Met Val Tyr Asp Met Glu Lys Gly Lys Phe  
 340 345 350  
 Pro Val Gln Leu Glu Asn Val Asp Ser Phe Val Glu Leu Gly Gln Val  
 355 360 365  
 Ala Leu Arg Thr Ser Leu Glu Leu Trp Met His Thr Asp Pro Val Ser  
 370 375 380  
 Gln Lys Asn Glu Ser Val Arg Asn Gln Val Glu Asp Leu Leu Ala Thr  
 385 390 395 400  
 Leu Glu Lys Ser Gly Ala Gly Val Pro Ala Val Ile Leu Arg Arg Pro  
 405 410 415  
 Asn Gln Ser Gln Pro Leu Pro Pro Ser Ser Leu Gln Arg Phe Leu Arg  
 420 425 430  
 Ala Arg Asn Ile Ser Gly Val Val Leu Ala Asp His Ser Gly Ala Phe  
 435 440 445  
 His Asn Lys Tyr Tyr Gln Ser Ile Tyr Asp Thr Ala Glu Asn Ile Asp  
 450 455 460  
 Val Ser Tyr Pro Glu Trp Leu Ser Pro Glu Glu Asp Leu Asn Phe Val  
 465 470 475 480

12/19

Thr Asp Thr Ala Lys Ala Leu Ala Asp Val Ala Thr Val Leu Gly Arg  
 485 490 495  
 Ala Leu Tyr Glu Leu Ala Gly Gly Thr Asn Phe Ser Asp Thr Val Gln  
 500 505 510  
 Ala Asp Pro Gln Thr Val Thr Arg Leu Leu Tyr Gly Phe Leu Ile Lys  
 515 520 525  
 Ala Asn Asn Ser Trp Phe Gln Ser Ile Leu Arg Gln Asp Leu Arg Ser  
 530 535 540  
 Tyr Leu Gly Asp Gly Pro Gln His Tyr Ile Ala Val Ser Ser Pro  
 545 550 555  
 Thr Asn Thr Thr Tyr Val Val Gln Tyr Ala Leu Ala Asn Leu Thr Gly  
 565 570 575  
 Thr Val Val Asn Leu Thr Arg Glu Gln Cys Gln Asp Pro Ser Lys Val  
 580 585 590  
 Pro Ser Glu Asn Lys Asp Leu Tyr Glu Tyr Ser Trp Val Gln Gly Pro  
 595 600 605  
 Leu His Ser Asn Glu Thr Asp Arg Leu Pro Arg Cys Val Arg Ser Thr  
 610 615 620  
 Ala Arg Leu Ala Arg Ala Leu Ser Pro Ala Phe Glu Leu Ser Gln Trp  
 625 630 635  
 Ser Ser Thr Glu Tyr Ser Thr Trp Thr Glu Ser Arg Trp Lys Asp Ile  
 645 650 655  
 Arg Ala Arg Ile Phe Leu Ile Ala Ser Lys Glu Leu Glu Leu Ile Thr  
 660 665 670  
 Leu Thr Val Gly Phe Gly Ile Leu Ile Phe Ser Leu Ile Val Thr Tyr  
 675 680 685  
 Cys Ile Asn Ala Lys Ala Asp Val Leu Phe Ile Ala Pro Arg Glu Pro  
 690 695 700  
 Gly Ala Val Ser Tyr  
 705

&lt;210&gt; 15

&lt;211&gt; 2250

&lt;212&gt; DNA

&lt;213&gt; mouse

&lt;400&gt; 15

cccagcgag aggcaacatg gctacgacta gggcgggcto tgggacctgac ccaggaagtc  
 60  
 ggggtctctt tcttctgtct ttttcogtg tactggcagg attgtgtggg ggaacctcag  
 120  
 tggagagaa aatctacatt cccttaata aacagctcc ttgtgtcgc ctgetcaacg  
 180  
 ccactatca gattgctgc cagtcttcaa ttagtgggga tacagggggt atccacgtag  
 240  
 tggagaaga agaagacctg aagtgggtgt tgaccgatgg ccccaacccc cttacatgg  
 300  
 ttctgttggg gggcaagctc ttcaccaag atgtaattga gaagctgaag ggaacaacca  
 360  
 gtagaatcgc tggctctgcc gtgactctag ccaagcccaa ctcaacttca agcttctctc  
 420  
 ctagtgtgca gtgcccaaat gatgggttg gtatttact caactctac gggccagagt  
 480  
 ttgtctactg caagaaaaca ctgtggaatg aactgggcaa cggtcttgct tatgaagact  
 540  
 ttagtttccc catctttctt ctggaagatg agaacgaaac caaggtcatc aagcagtgc  
 600

13/19

atcaagatca caacctgggt cagaatggct ctgcaccaag ctccccattg tgtgctatgc  
660  
agctcttctc acacatgcac gccgtcatca gcactgccac ctgcatgcgg cgcagcttca  
720  
tccagagcac cttcagcatc aaccagaaa tcgtctgtga ccccttatct gactacaacg  
780  
tatggagcat gcttaagcct ataaatacat ctgtgggact agaacctgac gtcagggtgtg  
840  
tggttgcggc cacacggctg gatagccggt cctttttctg gaattgtggc ccaggggctg  
900  
aaagtgcgtg agcctccttt gtcactcagc tggctgcagc tgaagctttg cacaaggcac  
960  
ctgatgtgac cactctatcc cgaaatgtga tgtttgtctt ctccagggg gaaacttttg  
1020  
actacattgg cagctcacg atggtctatg atatggagaa cggaagttt cccgtgcggc  
1080  
tcgagaacat cgactccttc gtggagctgg gacaggtggc cctaagaact tcactagatc  
1140  
tctggatgca cacagatccc atgtctcaga aaaatgagtc tgtgaaaaac caggtggagg  
1200  
tcttctggc cactctggag aagagcggtg ctgggtgcc tgaagtgtc ctgaggagac  
1260  
tggcccaagtc ccaggccctt ccacctctat ctctacaacg atttcttcgg gctcgaatac  
1320  
tctctggcgt ggtcctggct gaccactctg gctccttcca caatcggtat taccagagca  
1380  
tttatgacac ggctgagaac attaatgtga cctatcctga gtggcagagc ccagaagagg  
1440  
acctcaactt tgtgacagac actgccaaagg cactggcgaa tgtggccaca gtgctggcgc  
1500  
gtgcactgta tgagcttgca ggaggaacca acttcagcag ctccatccag gctgatcccc  
1560  
agacagttac acgtctgctc tatgggttcc tgggtaaagc taacaactca tggtttcagt  
1620  
cgatcctgaa acatgacctc aggtcctatt tggatgacag gcctcttcaa cactacatcg  
1680  
ccgtctccag ccctaccaac acgacttacg ttgtgcagta cgccttggca aacctgactg  
1740  
gcaaggcgac caacctcacc cgagagcagt gccaggatcc aagtaaagtc ccaaatgaga  
1800  
gcaaggattt atatgaatac tcgtgggtac aaggcccttg gaattccaac aggacagaga  
1860  
ggctccca ca gtgtgtgcgc tccacagtgc gaactgccag ggccttgtcc cctgcctttg  
1920  
aactgagtc gtggagctcc acagaatact ctacgtgggc ggagagccgc tggaaagaca  
1980  
tccaagctcg gatattccta attgccagca aaaagcttga gttcatcacg ctgatcgtgg  
2040  
gcttcagcat ccttatcttc tctctcatcg tcacctactg catcaatgcc aaagccgacg  
2100  
tccttthygt tgctccccga gagccaggag ctgtgtctta ctgaagagga ctctagctct  
2160  
ccctgcctgc tctgaacttt acttcccaga ccaggtgtcc ggctgggaac aaaccactaa  
2220  
tttgtcactg gactgtctct gggcctgctt  
2250

14/19

<210> 16  
 <211> 708  
 <212> PRT  
 <213> mouse

<400> 16  
 Met Ala Thr Thr Arg Gly Gly Ser Gly Pro Asp Pro Gly Ser Arg Gly  
 1 5 10 15  
 Leu Leu Leu Leu Ser Phe Ser Val Val Leu Ala Gly Leu Cys Gly Gly  
 20 25 30  
 Asn Ser Val Glu Arg Lys Ile Tyr Ile Pro Leu Asn Lys Thr Ala Pro  
 35 40 45  
 Cys Val Arg Leu Leu Asn Ala Thr His Gln Ile Gly Cys Gln Ser Ser  
 50 55 60  
 Ile Ser Gly Asp Thr Gly Val Ile His Val Val Glu Lys Glu Asp  
 65 70 75 80  
 Leu Lys Trp Val Leu Thr Asp Gly Pro Asn Pro Pro Tyr Met Val Leu  
 85 90 95  
 Leu Glu Gly Lys Leu Phe Thr Arg Asp Val Met Glu Lys Leu Lys Gly  
 100 105 110  
 Thr Thr Ser Arg Ile Ala Gly Leu Ala Val Thr Leu Ala Lys Pro Asn  
 115 120 125  
 Ser Thr Ser Ser Phe Ser Pro Ser Val Gln Cys Pro Asn Asp Gly Phe  
 130 135 140  
 Gly Ile Tyr Ser Asn Ser Tyr Gly Pro Glu Phe Ala His Cys Lys Lys  
 145 150 155 160  
 Thr Leu Trp Asn Glu Leu Gly Asn Gly Leu Ala Tyr Glu Asp Phe Ser  
 165 170 175  
 Phe Pro Ile Phe Leu Leu Glu Asp Glu Asn Glu Thr Lys Val Ile Lys  
 180 185 190  
 Gln Cys Tyr Gln Asp His Asn Leu Gly Gln Asn Gly Ser Ala Pro Ser  
 195 200 205  
 Phe Pro Leu Cys Ala Met Gln Leu Phe Ser His Met His Ala Val Ile  
 210 215 220  
 Ser Thr Ala Thr Cys Met Arg Arg Ser Phe Ile Gln Ser Thr Phe Ser  
 225 230 235 240  
 Ile Asn Pro Glu Ile Val Cys Asp Pro Leu Ser Asp Tyr Asn Val Tip  
 245 250 255  
 Ser Met Leu Lys Pro Ile Asn Thr Ser Val Gly Leu Glu Pro Asp Val  
 260 265 270  
 Arg Val Val Val Ala Ala Thr Arg Leu Asp Ser Arg Ser Phe Phe Tip  
 275 280 285  
 Asn Val Ala Pro Gly Ala Glu Ser Ala Val Ala Ser Phe Val Thr Gln  
 290 295 300  
 Leu Ala Ala Ala Glu Ala Leu His Lys Ala Pro Asp Val Thr Thr Leu  
 305 310 315 320  
 Ser Arg Asn Val Met Phe Val Phe Phe Gln Gly Glu Thr Phe Asp Tyr  
 325 330 335  
 Ile Gly Ser Ser Arg Met Val Tyr Asp Met Glu Asn Gly Lys Phe Pro  
 340 345 350  
 Val Arg Leu Glu Asn Ile Asp Ser Phe Val Glu Leu Gly Gln Val Ala  
 355 360 365  
 Leu Arg Thr Ser Leu Asp Leu Trp Met His Thr Asp Pro Met Ser Gln  
 370 375 380  
 Lys Asn Glu Ser Val Lys Asn Gln Val Glu Asp Leu Leu Ala Thr Leu  
 385 390 395 400  
 Glu Lys Ser Gly Ala Gly Val Pro Glu Val Val Leu Arg Arg Leu Ala  
 405 410 415



15/19

Gln Ser Gln Ala Leu Pro Pro Ser Ser Leu Gln Arg Phe Leu Arg Ala  
 420 425 430  
 Arg Asn Ile Ser Gly Val Val Leu Ala Asp His Ser Gly Ser Phe His  
 435 440 445  
 Asn Arg Tyr Tyr Gln Ser Ile Tyr Asp Thr Ala Glu Asn Ile Asn Val  
 450 455 460  
 Thr Tyr Pro Glu Trp Gln Ser Pro Glu Glu Asp Leu Asn Phe Val Thr  
 465 470 475 480  
 Asp Thr Ala Lys Ala Leu Ala Asn Val Ala Thr Val Leu Ala Arg Ala  
 485 490 495  
 Leu Tyr Glu Leu Ala Gly Gly Thr Asn Phe Ser Ser Ser Ile Gln Ala  
 500 505 510  
 Asp Pro Gln Thr Val Thr Arg Leu Leu Tyr Gly Phe Leu Val Lys Ala  
 515 520 525  
 Asn Asn Ser Trp Phe Gln Ser Ile Leu Lys His Asp Leu Arg Ser Tyr  
 530 535 540  
 Leu Asp Asp Arg Pro Leu Gln His Tyr Ile Ala Val Ser Ser Pro Thr  
 545 550 555 560  
 Asn Thr Thr Tyr Val Val Gln Tyr Ala Leu Ala Asn Leu Thr Gly Lys  
 565 570 575  
 Ala Thr Asn Leu Thr Arg Glu Gln Cys Gln Asp Pro Ser Lys Val Pro  
 580 585 590  
 Asn Glu Ser Lys Asp Leu Tyr Glu Tyr Ser Trp Val Gln Gly Pro Trp  
 595 600 605  
 Asn Ser Asn Arg Thr Glu Arg Leu Pro Gln Cys Val Arg Ser Thr Val  
 610 615 620  
 Arg Leu Ala Arg Ala Leu Ser Pro Ala Phe Glu Leu Ser Gln Trp Ser  
 625 630 635 640  
 Ser Thr Glu Tyr Ser Thr Trp Ala Glu Ser Arg Trp Lys Asp Ile Gln  
 645 650 655  
 Ala Arg Ile Phe Leu Ile Ala Ser Lys Lys Leu Glu Phe Ile Thr Leu  
 660 665 670  
 Ile Val Gly Phe Ser Ile Leu Ile Phe Ser Leu Ile Val Thr Tyr Cys  
 675 680 685  
 Ile Asn Ala Lys Ala Asp Val Leu Phe Val Ala Pro Arg Glu Pro Gly  
 690 695 700  
 Ala Val Ser Tyr  
 705

<210> 17  
 <211> 2942  
 <212> DNA  
 <213> D. melanogaster

<400> 17  
 tctgatatac tcgcactgt gctgggaatt cgccacgagc gcaacactgc aattctgga  
 60  
 cgcgatttcg tgggaattctt cgtatggaat gcgtctgaat gcgcttcca tatggtgtt  
 120  
 aatactgtcg tatggagcaa ctattgctca aggagaaaga acccgcata agatgtacga  
 180  
 gccattgga ggagctagct gtttccgacg gctgaatggc acccatcaga cagctgttc  
 240  
 ctcaacctac tccggttcg tggcgctact acatctaata aacgtcgagg cgcacctgga  
 300  
 attcttctt agcagccac catctccacc ttacgcccc atgataccac ctcaactgtt  
 360

cacacgtaac aacctgatgc gcctaaggga agccggacca aagaacattt ctgtggtgct  
420  
gctgatcaac cgcacgaacc agatgaagca gtctcgcac gaactcaact gcccaaatca  
480  
gtacacggcg ctaaacagca ccagtgaagc ctgcgacgac agcaatccag ccaaaaactg  
540  
gaatccctgg ggcactggac ttctgcacga ggactttccc ttctctatct attacatagg  
600  
cgatttggat caggtcacca agctagagaa gtgctttcag gactttaaca accataacta  
660  
cgagacgac gcgctgctga gcttgcgcgc cgtcgaggtc aagtccttta tgcgcgccgc  
720  
tgtcaacacc gaggtctgta tgcgcgcgac caacttcac aataactctg gaggaagcaa  
780  
gtactcgcat ccgctcgagg gacggaatgt ttgcaccact tgtacccccc aaagccagca  
840  
atcggaacaa actttggaga cagtcctac gaatgaaaag ttcatattag taacctgtcg  
900  
cctggacacc accaccatgt tcgatggcgt cggctctgga gccatggact ccctcatggg  
960  
attttcgtgt ttactcatg tggcgtatct attaaaacaa ctacttcgcg cgcaaagcaa  
1020  
agaccttcac aatgtcctct ttgtgacttt taatggcgaa tcctatgact acattgggtc  
1080  
tcaagagatt gtatacgaca tggagaaact tcaatttcct actgaatcca caggcacgcc  
1140  
tcgattgccc ttgacaata ttgacttcac gctggacatc gggacactgg atgacatac  
1200  
gaatattaag ctgcatcgct taaatggaac gactttggct cagcaaatc tagagcggtc  
1260  
aaataactat gcgaagtcgc cagcctatgg ctttaacctg aacattcagt ccgagatgag  
1320  
cgctcactta ccacctacgt cggcgcaatc atttctcgca cgtgatccaa acttcaatgc  
1380  
attgattcta aacgctcgtc caacgaacaa gtattatcat tccacatacg atgacggga  
1440  
taacgtggac ttacactatg cgaacacaag caaggatttc acccagctga cggaaagttaa  
1500  
tgactttaaa agcttgaaac cagattcact gcaaatgaaa gtgcgcaacg ttctctctat  
1560  
tgtggccatg gccctatc acacaataac tggaaaggag tacactggca ccaagtgggc  
1620  
caaccctctg atggcagatg agttccttta ctgtttcctg caatcggcgg actgccact  
1680  
ctttaaggcc gcactcttate cgggcagtc gctcaccaat ttgectccga tgcgctacat  
1740  
aagcgtcttg ggtggctctc aagagtcgtc gggctatacg tatagattgc tgggctatct  
1800  
ctgtcaciaa ctgcagccag acattcacag agataactgc accgacttgc cgctgcacta  
1860  
tttcgccgga ttcaacaata tcggagagtgc tgcctcacc acgcagaact acagtcacgc  
1920  
cctgagtcca gcttttctta ttgatggcta cgattggagt tccggcatgt attccacttg  
1980  
gactgaatcc acctggtcac agttcagtc acgcatcttc ctgcgccctg ccaatgttca  
2040  
ccaggtcaca actctaagcg ttggcatagt ggtgctgata atatcctctt gtttgggtga  
2100

17/19

tataatcagc tcacgatcgg aagtcctctt tgaggatttg ccggcaagca atgccgcatt  
 2160  
 atttggttga tgtcacaact gccacagcga cgaatcctc gcgttcagca gctcattcca  
 2220  
 tagattttctg catgcgtaaa ctaaacgtta cttgtaaacc aatcgattaa gaattttctga  
 2280  
 ttgtgccctt ttagatcgcc gcggccgaca gctgttataa tcttcaaaga atatctgttc  
 2340  
 acgtgcccga gatgattggt tgctgaatat gatctaaaaa aaaaaacaga cttacaaaag  
 2400  
 acactaaaat gatattctaa ctctctttat ttaaaacatt aagcaaacgt ttattttat  
 2460  
 gtatttttgt attttaaagt agtaaatag ctctatcaa ctacgttgta tcatatatag  
 2520  
 acatttaacc aattgcgaca aaattctttc cactgtccg gccctttttg cattgtacat  
 2580  
 aggattaacc aacccaattg aacctctgat aatgccaaag aagagatgct tgtacaaaata  
 2640  
 ttgacaagaa actgctataa cttataaatc actggaataa tttatacctt ctgcacttat  
 2700  
 tgcgatactg aacttaatga tctgaaatca ttacttcata gaagacaaat aattattata  
 2760  
 acgactttta attatatatg ttaataaat tttgataaag tgtaaaagca tgcctgtta  
 2820  
 tctagttagg ttattttcaa ggcaattatt cacagctctc agattccaac gattgatgta  
 2880  
 gtttaatctc aactctttac caaagaagtc catttgtaact agtgtaaaag atattttcaa  
 2940  
 ta  
 2942

<210> 18  
 <211> 695  
 <212> PRT  
 <213> D. melanogaster

<400> 18

Met	Glu	Met	Arg	Leu	Asn	Ala	Ala	Ser	Ile	Trp	Leu	Leu	Ile	Leu	Ser
1				5				10						15	
Tyr	Gly	Ala	Thr	Ile	Ala	Gln	Gly	Glu	Arg	Thr	Arg	Asp	Lys	Met	Tyr
				20				25						30	
Glu	Pro	Ile	Gly	Gly	Ala	Ser	Cys	Phe	Arg	Arg	Leu	Asn	Gly	Thr	His
				35				40						45	
Gln	Thr	Gly	Cys	Ser	Ser	Thr	Tyr	Ser	Gly	Ser	Val	Gly	Val	Leu	His
				50				55						60	
Leu	Ile	Asn	Val	Glu	Ala	Asp	Leu	Glu	Phe	Leu	Leu	Ser	Ser	Pro	Pro
				65				70						75	
Ser	Pro	Pro	Tyr	Ala	Pro	Met	Ile	Pro	Pro	His	Leu	Phe	Thr	Arg	Asn
				85				90						95	
Asn	Leu	Met	Arg	Leu	Lys	Glu	Ala	Gly	Pro	Lys	Asn	Ile	Ser	Val	Val
				100				105						110	
Leu	Leu	Ile	Asn	Arg	Thr	Asn	Gln	Met	Lys	Gln	Phe	Ser	His	Glu	Leu
				115				120						125	
Asn	Cys	Pro	Asn	Gln	Tyr	Ser	Gly	Leu	Asn	Ser	Thr	Ser	Glu	Thr	Cys
				130				135						140	
Asp	Ala	Ser	Asn	Pro	Ala	Lys	Asn	Trp	Asn	Pro	Trp	Gly	Thr	Gly	Leu
				145				150						155	
														160	

18/19

Leu His Glu Asp Phe Pro Phe Pro Ile Tyr Tyr Ile Ala Asp Leu Asp  
 165 170 175  
 Gln Val Thr Lys Leu Glu Lys Cys Phe Gln Asp Phe Asn Asn His Asn  
 180 185 190  
 Tyr Glu Thr His Ala Leu Arg Ser Leu Cys Ala Val Glu Val Lys Ser  
 195 200 205  
 Phe Met Ser Ala Ala Val Asn Thr Glu Val Cys Met Arg Arg Thr Asn  
 210 215 220  
 Phe Ile Asn Asn Leu Gly Gly Ser Lys Tyr Cys Asp Pro Leu Glu Gly  
 225 230 235 240  
 Arg Asn Val Ser Pro Cys Thr Pro Glu Ser Gln Gln Ser Glu Thr  
 245 250 255  
 Thr Leu Glu Thr Val His Thr Asn Glu Lys Phe Ile Leu Val Thr Cys  
 260 265 270  
 Arg Leu Asp Thr Thr Thr Met Phe Asp Gly Val Gly Leu Gly Ala Met  
 275 280 285  
 Asp Ser Leu Met Gly Phe Ala Val Phe Thr His Val Ala Tyr Leu Leu  
 290 295 300  
 Lys Gln Leu Leu Pro Pro Gln Ser Lys Asp Leu His Asn Val Leu Phe  
 305 310 315 320  
 Val Thr Phe Asn Gly Glu Ser Tyr Asp Tyr Ile Gly Ser Gln Arg Phe  
 325 330 335  
 Val Tyr Asp Met Glu Lys Leu Gln Phe Pro Thr Glu Ser Thr Gly Thr  
 340 345 350  
 Pro Pro Ile Ala Phe Asp Asn Ile Asp Phe Met Leu Asp Ile Gly Thr  
 355 360 365  
 Leu Asp Asp Ile Ser Asn Ile Lys Leu His Ala Leu Asn Gly Thr Thr  
 370 375 380  
 Leu Ala Gln Gln Ile Leu Glu Arg Leu Asn Asn Tyr Ala Lys Ser Pro  
 385 390 395 400  
 Arg Tyr Gly Phe Asn Leu Asn Ile Gln Ser Glu Met Ser Ala His Leu  
 405 410 415  
 Pro Pro Thr Ser Ala Gln Ser Phe Leu Arg Arg Asp Pro Asn Phe Asn  
 420 425 430  
 Ala Leu Ile Leu Asn Ala Arg Pro Thr Asn Lys Tyr Tyr His Ser Thr  
 435 440 445  
 Tyr Asp Asp Ala Asp Asn Val Asp Phe Thr Tyr Ala Asn Thr Ser Lys  
 450 455 460  
 Asp Phe Thr Gln Leu Thr Glu Val Asn Asp Phe Lys Ser Leu Asn Pro  
 465 470 475 480  
 Asp Ser Leu Gln Met Lys Val Arg Asn Val Ser Ser Ile Val Ala Met  
 485 490 495  
 Ala Leu Tyr Gln Thr Ile Thr Gly Lys Glu Tyr Thr Gly Thr Lys Val  
 500 505 510  
 Ala Asn Pro Leu Met Ala Asp Glu Phe Leu Tyr Cys Phe Leu Gln Ser  
 515 520 525  
 Ala Asp Cys Pro Leu Phe Lys Ala Ala Ser Tyr Pro Gly Ser Gln Leu  
 530 535 540  
 Thr Asn Leu Pro Pro Met Arg Tyr Ile Ser Val Leu Gly Gly Ser Gln  
 545 550 555 560  
 Glu Ser Ser Gly Tyr Thr Tyr Arg Leu Leu Gly Tyr Leu Leu Ser Gln  
 565 570 575  
 Leu Gln Pro Asp Ile His Arg Asp Asn Cys Thr Asp Leu Pro Leu His  
 580 585 590  
 Tyr Phe Ala Gly Phe Asn Asn Ile Gly Glu Cys Arg Leu Thr Thr Glu  
 595 600 605  
 Asn Tyr Ser His Ala Leu Ser Pro Ala Phe Leu Ile Asp Gly Tyr Asp  
 610 615 620

19/19

```

Trp Ser Ser Gly Met Tyr Ser Thr Trp Thr Glu Ser Thr Trp Ser Gln
625                               630                               635                               640
Phe Ser Ala Arg Ile Phe Leu Arg Pro Ser Asn Val His Gln Val Thr
                               645                               650                               655
Thr Leu Ser Val Gly Ile Val Val Leu Ile Ile Ser Phe Cys Leu Val
                               660                               665                               670
Tyr Ile Ile Ser Ser Arg Ser Glu Val Leu Phe Glu Asp Leu Pro Ala
675                               680                               685
Ser Asn Ala Ala Leu Phe Gly
690                               695

```

```

<210> 19
<211> 17
<212> PRT
<213> human

```

```

<400> 19

```

```

Ala Arg Leu Ala Arg Ala Leu Ser Pro Ala Phe Glu Leu Ser Gln Trp
1      5      10      15
Ser

```

## INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/CA 00/00354

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C07K14/705 A01K67/027 C12N5/10 C12Q1/68  
G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K A01K C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

MEDLINE, BIOSIS, STRAND, EPO-Internal

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	NAGASE T ET AL : "Hypothetical protein KIAA0253" SWISSPROT DATABASE ENTRY Y253_HUMAN, ACCESSION NUMBER Q92542, 15 July 1998 (1998-07-15), XP002143447 cited in the application sequence	1,2
X	NAGASE T ET AL: "Human mRNA for KIAA0253 gene" EMBL DATABASE ENTRY HSD442, ACCESSION NUMBER D87442, 9 November 1996 (1996-11-09), XP002143448 cited in the application sequence	7
	— — — — — -/-	

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

## \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"B" document member of the same patent family

Date of the actual completion of the international search

26 July 2000

Date of mailing of the international search report

07/08/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5816 Patenlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 apo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Espen, J

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/CA 00/00354

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JONES SJM: "hypothetical 81.4 kd protein zc434-6" SWISSPROT YHC6_CAEEL, ACCESSION NUMBER Q23316, 15 July 1998 (1998-07-15), XP002143449 cited in the application sequence	1,3
A	YU G ET AL: "The presenilin 1 protein is a component of a high molecular weight intracellular complex that contains beta-catenin." JOURNAL OF BIOLOGICAL CHEMISTRY, (1998 JUN 26) 273 (26) 16470-5. , XP000925470 cited in the application	
A	LEVESQUE G ET AL: "Presenilins interact with armadillo proteins including neural-specific plakophilin-related protein and beta-catenin." JOURNAL OF NEUROCHEMISTRY, (1999 MAR) 72 (3) 999-1008. , XP000925514	